<PAGE>

                                                                    Exhibit 10.2

                              SUBLICENSE AGREEMENT

                                     between

                               Novartis Pharma AG

                                       and

                           Vanda Pharmaceuticals, Inc.

----------
CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

<PAGE>

SUBLICENSE AGREEMENT

THIS SUBLICENSE AGREEMENT effective as of the 4th day of June, 2004, ("Effective
Date") between Vanda Pharmaceuticals, Inc., a corporation organized and existing
under the laws of the State of Delaware and having its principal office at 47
Hulfish Street, Suite 310, Princeton, NJ 08542, The United States ("Vanda") and
Novartis Pharma AG, a corporation organized under the laws of Switzerland and
having its principal office at Lichtstrasse 35, CH-4056 Basel, Switzerland
("Novartis")

WITNESSETH THAT:

WHEREAS Novartis is the exclusive worldwide licensee of Titan Pharmaceuticals,
Inc. ("Titan") under a sublicense agreement between Novartis and Titan having an
Effective Date of 20th November, 1997 and as amended by two Amendments between
the parties dated 30th November 1998 and 10th April, 2001 (the "Titan
Agreement"); and

WHEREAS Titan is the exclusive worldwide licensee of Hoechst Marion Roussel Inc.
("HMRI") under a license agreement between Titan and HMRI having an Effective
Date of 31st December, 1996 (the "HMRI Agreement"); and

WHEREAS as a result of corporate restructuring, Aventis Pharmaceuticals Inc., a
corporation organized under the laws of the State of Delaware and with offices
at 200 Crossing Boulevard, Bridgewater, NJ 08807-0890 ("Aventis") acquired
substantially all of the tangible operating assets of HMRI and, as a result, the
HMRI Agreement has been assigned to Aventis; and

WHEREAS under such Titan Agreement and the Novartis Patents, Novartis has rights
with respect to certain patents and patent applications, identified in APPENDIX
A hereto, and know-how relating to a compound known as Iloperidone; and

WHEREAS Vanda desires to obtain certain exclusive licenses from Novartis under
the Titan Agreement and the Novartis Patents, and Novartis is willing to grant
to Vanda such licenses;

NOW, THEREFORE, in consideration of the covenants and obligations expressed
herein, and intending to be legally bound, the parties agree as follows:


                                  Page 2 of 56

<PAGE>

1. DEFINITIONS

1.1 "Affiliate" shall mean any corporation, firm, partnership or other entity,
whether de jure or de facto, which directly or indirectly owns, is owned by or
is under common ownership with a party to this Sublicense Agreement, to the
extent of more than fifty percent (50%) of the equity (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) having the power to direct the affairs of the entity
and any person, firm, partnership, corporation or other entity actually
controlled by, controlling or under common control with a party to this
Sublicense Agreement.

1.2 "Commercially Reasonable Efforts" shall mean efforts and resources
customarily used in the pharmaceutical business for a product of a market
potential similar to the market potential of Product under evaluation, at a
similar stage of its product life, taking into account the establishment of the
product in the marketplace, the competitiveness of the marketplace, the
proprietary position of the product, regulatory status involved, and the
profitability of the product.

1.3 "Competitive Industry Standard Level" shall mean the level to which the
Product shall be marketed by or on behalf of Vanda, its Affiliates or
Sublicensees in the countries of the Territory where Patents are issued and
enforced with at least the same diligence that Vanda would use in marketing its
own products in such countries, in a manner consistent with the effort devoted
by the pharmaceutical industry to products having the same or similar potential
value of the Product in those countries when the Product is launched.

1.4 "Compound" shall mean the chemical compound known as Iloperidone, whose
specific chemical name is [*], including any salts, hydrates, solvates, and/or
stereoisomers thereof, and only the metabolites listed in APPENDIX B hereto,
including any salts, hydrates, solvates and/or stereoisomers of such
metabolites.

1.5 "EEA" shall mean the European Economic Area, which consists of the European
Union and Iceland, Liechtenstein and Norway.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 3 of 56

<PAGE>

1.6 "European Union" shall mean the member states of the European Union, as may
exist from time to time, which as of the date hereof include Austria, Belgium,
Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the
Netherlands, Portugal, Spain, Sweden and the United Kingdom and all other
countries which accede to the European Union during the term of this Sublicense
Agreement.

1.7 "Exclusive" shall have the meaning specified in Section 2.1 hereof.

1.8 "FDA" shall mean the United States Food and Drug Administration.

1.9 "FD&C Act" shall mean the Federal Food, Drug and Cosmetic Act (21 U.S.C.
301ff), as amended from time to time.

1.10 "Field" shall mean application to all conditions, disorders and diseases in
humans.

1.11 "IND" shall mean an Investigational New Drug Application.

1.12 "Know-How" shall mean all technical information and know-how: (a) presently
developed and owned or controlled by HMRI or Titan and their Affiliates and made
available to Novartis, (b) developed and owned or controlled by Novartis and its
Affiliates after the date of the Titan Agreement, and (c) developed and owned or
controlled by HMRI, Titan or Novartis and their respective Affiliates, after the
date hereof and included within this definition of "Know-How" by operation of
Section 2.3 hereof, which relates to the Compound or Product in the Field and
which constitutes a proprietary "trade secret" or other valid intellectual
property right under U.S. or other applicable law which is substantial, secret
and identifiable, including, without limitation, all biological, chemical,
pharmacological, toxicological, clinical, regulatory, analytical, quality
control and manufacturing data and any other information (whether technical or
commercial) relating to the Compound or Product that may be useful for the
development, regulatory approval, manufacture and commercialization of the
Compound or Product.

1.13 "Major Market Country" shall mean each of France, Germany, Italy, Spain and
the United Kingdom.


                                  Page 4 of 56

<PAGE>

1.14 "NDA" shall mean any and all applications (new drug applications) submitted
to the FDA under Sections 505, 507 or 512 of the FD&C Act and applicable
regulations related to the Product, including without limitation, full NDAs,
"paper" NDAs and abbreviated NDAs (ANDAs) and all amendments and supplements
thereto or equivalent applications in the European Union.

1.15 "Net Sales" shall be calculated as follows: From the gross invoice price of
the Product sold by Vanda or its Affiliates or Sub-licensees to independent
third parties in bona fide, arms-length transactions there shall be subtracted,
if not previously deducted in the amount invoiced or received, (i) quantity and
cash discounts actually allowed or taken, (ii) freight, postage and shipping
insurance allocated in accordance with Vanda's standard allocation procedure,
(iii) customs duties and taxes, if any, directly related to the sale, (iv)
amounts repaid or credited by reason of rejections, return of goods and
retroactive price reductions mandated by or granted in response to state,
provincial or federal law or regulation and specifically identifiable as
relating to the Product, (v) amounts incurred as a result of governmental (or
governmental agency) mandated rebate programmes, (vi) third party rebates and
wholesale chargebacks related to the sale of the Product to the extent actually
allowed and (vii) as agreed by the parties in writing, any other specifically
identifiable amounts included in the Product's gross sales that were or
ultimately will be credited and that are substantially similar to those listed
above. The computation of Net Sales shall not include sales between or among a
party and its Affiliates or Sub-licensees, except where such Affiliates or
Sub-licensees are end users. For the purposes of this Sublicense Agreement,
sales of the Product to independent distributors, wholesalers or other parties
who purchase and take title to the Product are considered to be sales to third
parties. If the Product is sold through intermediaries such as agents or
co-promoters who do not purchase and take title to the Product, royalties shall
be due on Net Sales to third parties who purchase the Product through such
intermediaries. It is agreed that there shall be no sales of the Compound to
Third Parties by or on behalf of Vanda, its Affiliates or Sub-licensees. In the
event there are sales of Compound to Third Parties by or on behalf of Vanda, its
Affiliates or Sub-licensees, such sales shall be subject to the payment of
royalties by Vanda to Novartis (as the case may be) to the same extent as
payments of royalties are due on sales of the Product pursuant to this
Sublicense Agreement.

In the event that the Product is sold as part of a combination product, the Net
Sales of the Product, for the purposes of determining royalty payments, shall be
determined by


                                  Page 5 of 56

<PAGE>

multiplying the Net Sales (as defined above in this Section) of the combination
product by the fraction A/(A+B), where A is the weighted (by sales volume)
average sale price of Product when sold separately in finished form and B is the
weighted average sale price of the other product(s) sold separately in finished
form. In the event that such average sale price cannot be determined for both
Product and the other product(s) in combination, Net Sales for purposes of
determining royalty payments shall be mutually agreed by the parties within a
reasonable period of time prior to the first commercial sale of such combination
product based on all relevant factors including relative cost and the relative
value contributed by each component, and such agreement shall not be
unreasonably withheld.

1.16 "Patents" shall mean all patents and patent applications set forth in
APPENDIX A, including continuations, continuations-in-part, divisions, patents
of addition, reissues, re-examinations, renewals or extensions thereof, along
with supplementary protection certificates and other administrative protection
of any kind in the Territory owned by or licensed to Novartis or its Affiliates
to the extent that such patents claim the Compound or Product, or use,
formulations or manufacture thereof, for use in the Field, but not any other
compound or use outside of the Field disclosed or claimed in those patents or
patent applications. Any Patent having claims covering the Compound or Product
or its use formulation and manufacture thereof for use in the Field which is
issued during the term of this Sublicense Agreement in any Country of the
Territory shall automatically be deemed as of the date of such issuance to be
included in the Patent, as defined hereunder.

1.17 "Product" shall mean any bulk or finished pharmaceutical composition
containing the Compound as a pharmaceutically active ingredient for use in the
Field, whether as a sole active ingredient or in combination with another active
ingredient.

1.18 "SEC" shall mean the United States Securities and Exchange Commission.

1.19 "Sub-licensee" shall mean a Third Party (as defined below) to whom a party
sublicenses rights to manufacture and sell (or have manufactured and sold) the
Compound under Patents, but shall not include any Third Parties to whom rights
to manufacture the Compound have not been granted. Unless such party grants to
such Third Party the right to manufacture Compound, the following Third Parties
shall not be considered Sublicensees under this Sublicense Agreement: agents,
distributors, wholesalers, subcontractors, co-marketers,


                                  Page 6 of 56

<PAGE>

co-promoters, partners or joint venturers. Sub-licensees shall not include
compulsory licensees as described in Section 4.1(a).

1.20 "Territory" shall mean all countries and territories of the world provided
that any country(ies) in which this Sublicense Agreement is terminated shall be
removed from the scope of this definition.

1.21 "Third Party" shall mean any party other than a party to this Sublicense
Agreement, HMRI, Titan or an Affiliate of any of these.

2. GRANT

2.1 Novartis hereby grants to Vanda an Exclusive sublicense in the Field under
the Patents (to the extent, but only to the extent, that such patents or patent
applications claim the Compound or Product or the manufacture, formulation, or
use thereof) and Know-How to develop, have developed, make, have made, use,
import, sell, offer for sale and have sold the Compound and Product in the
Territory, subject to the terms and conditions of this Sublicense Agreement. All
rights granted by Novartis to Vanda in this Sublicense Agreement shall remain
subject to the rights and obligations of HMRI and Titan within the HMRI
Agreement. The sublicense granted to Vanda by Novartis shall include the right
of Vanda to sublicense its rights under this Sublicense Agreement, but only upon
Novartis', HMRI's and Titan's prior written consent, which consent shall not be
unreasonably withheld. Any such sublicensee(s) shall impose upon a
Sublicencee(s) of Vanda substantially the same terms and conditions as Vanda
assumes in this Sublicense Agreement. As used in this Sublicense Agreement, the
term "Exclusive" shall mean that neither Novartis, nor its Affiliates shall
grant any other license to, nor themselves exploit, the Patents and Know-How
with respect to the Compound and Product in the Field (unless otherwise
specified herein) and be limited as follows:

(a) With respect to all geographic areas outside of the EEA, such sublicense
shall be exclusive for the duration and validity of the intellectual property
rights constituting the Patents and/or Know-How.

(b) With respect to all geographic areas within the EEA, such sublicense shall
be exclusive for the following time periods:


                                  Page 7 of 56

<PAGE>

     (i) For each of the countries within the EEA where only Patents (and not
     Know-How) exist and are sublicensed to Vanda hereunder, the period of
     exclusivity for each such country shall be limited to the duration of the
     relevant Patents in such country, provided that "Patents" for the purposes
     of the interpretation of this paragraph shall be limited to patents
     existing, and patents issuing from patent applications existing, and
     patents issuing from patent applications covering inventions existing as of
     the date of the Titan Agreement;

     (ii) For each of the countries within the EEA where Patents and Know-How
     exist and are sublicensed to Vanda hereunder, the period of exclusivity for
     each such country shall be limited to the duration of the relevant Patents
     in such Country, provided that "Patents" for purposes of the interpretation
     of this paragraph shall be limited to patents existing, and patents issuing
     from patent applications existing, as of the date of the Titan Agreement
     and, provided, further, that if the duration of such Patents is less than
     ten (10) years from the date of first marketing of the Product in the EEA
     but the Know-How continues to be sublicensed hereunder, the duration of
     exclusivity shall be for ten (10) years from the date of first marketing of
     the Product in the EEA; and

     (iii) For each of the countries within the EEA where Know-How (and not
     Patents) exists and is sublicensed to Vanda hereunder, the period of
     exclusivity for each such country shall be limited to ten (10) years from
     the date of first marketing of the Product in the EEA. Thereafter, such
     sublicense within the EEA shall be on a non-exclusive basis.

(c) deleted

(d) Novartis and its Affiliates and licensed Third Parties and Sub-licensees
shall also be entitled to utilise the Patents and Know-How in the Field within
the Territory for the development and manufacture of the Compound and Product
for marketing, distribution and sale where Vanda's rights under this
Sublicense Agreement have been terminated. The duration of the sublicense
granted by this Section 2.1 shall be limited to the duration, on a
country-by-country basis, of the intellectual property rights which comprise the
Patents and Know-How with respect to a relevant country, provided that the
termination of any portion of any sublicense shall be without prejudice to the
requirement of Vanda to pay royalties pursuant to the terms of this Sublicense
Agreement. Notwithstanding the foregoing but subject to Sections 3.4 and 3.5
hereof, Novartis acknowledges and agrees that Vanda shall have the right to
continue to use on a royalty-free, non-exclusive basis the information which


                                  Page 8 of 56

<PAGE>

constitutes the Patents and Know-How on a country-by-country basis in the
Territory for the Field after the Patents expire or cease to be valid or
enforceable and/or Know-How has entered into the public domain.

2.2 deleted

2.3 deleted.

2.4 Novartis grants to Vanda a non-exclusive, worldwide sublicense to make or
use any analytical reference standards, intermediate or metabolite of the
Compound or Product not listed in Appendix B hereto which may be claimed in
Patents limited solely to making or using the Compound or Product. The foregoing
sublicense shall include the right to sublicense, but only upon the prior
written consent of each of HMRI, Titan and Novartis which consent shall not be
unreasonably withheld. Any such sublicense shall impose upon the Sublicensee(s)
substantially the same terms and conditions as Vanda assumes in this Sublicense
Agreement.

2.5 Vanda shall promote, market and sell the Product under a registered
trademark(s) approved by HMRI, Titan and Novartis. Vanda will promptly inform
HMRI, Titan and Novartis of the selected trademark(s) and each of the three
parties will have twenty (20) business days in which to either approve or reject
the selection(s). Vanda shall be responsible for the selection and registration
of such trademark(s) in all countries of the Territory at its own cost. In the
event the sublicense granted hereunder is terminated in a particular country,
other than pursuant to Section 10.3 or as a result of Vanda's termination of
this Sublicense Agreement for breach pursuant to Section 10.5, and Novatis
exercises the right to promote, market or sell the Product in such country then
upon Novartis' request (a) Vanda shall grant to Novartis or its designee(s) a
trademark license at a royalty to be negotiated in good faith (which royalty
shall not be less than [*] percent ([*]%) and no more than [*] percent ([*]%) on
Net Sales of the Product by Novartis and/or its designees) at such time to use
such trademark in connection with marketing the Product in such country, subject
to reasonable quality control by Vanda with respect to the Product sold under
this Section 2.5(a), or (b) Novartis or its designee(s) shall select and
register at Novartis' cost a trademark of its own in connection with the
marketing of the Product in such country, provided such Novartis trademark is
not in any way confusingly similar to the Vanda trademark. Novartis shall use
the trademark that

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 9 of 56

<PAGE>

that party acting alone has chosen as a trademark (rather than a Vanda
trademark) in promoting, marketing or selling the Product in any country that is
a member of a free trade union or other economic grouping (e.g., the European
Union, EEA, NAFTA, ASEAN and ANDEAN Pact countries) where Vanda is promoting,
marketing or selling the Product under a Vanda trademark.

2.6 If Vanda notifies Novartis in writing that Vanda (and/or its Affiliate(s))
is not willing or does not have the capability itself or cannot enter into a
Sublicense or other agreement (providing the necessary expertise and resources)
in country(ies) outside those covered by NAFTA and the European Union to:(a)
develop the Compound or Product (as the case may warrant), and (b) manufacture
the Compound and/or market the Product (as the case may warrant) at a
Competitive Industry Standard Level at the date of Product approval in such
country(ies), then Novartis shall have the right to terminate the sublicense
granted by this Sublicense Agreement but only with respect to such country(ies),
unless the parties agree in writing to extend such time frame.

2.7 If the Product is not launched in the United States or a Major Market
Country at a Competitive Industry Standard Level by Vanda, its Affiliate and/or
Sublicensee within [*] after the date of receiving the approvals necessary to
commercialise the Product in the United States or a Major Market Country Vanda
and Novartis shall review the progress of launch efforts, it being understood
that the parties, at the request of a party, may review the progress of launch
efforts prior to the end of such [*] period, and Vanda shall keep Novartis and
HMRI informed on a regular basis of the status of its launch efforts after
receiving the approvals necessary to commercialize the Product in the United
States or a Major Market Country until such time that launch is achieved in the
United States or a Major Market Country. If launch in the United States or a
Major Market Country is not achieved within one (1) year after the date of
receiving the approvals necessary to commercialize the Product in such
country(ies) (circumstances shall not include events of force majeure as defined
in Section 13), or in any event within two (2) years after Product approval then
the sublicense granted by this Sublicense Agreement shall terminate, but only
with respect to the particular country where launch was not achieved within such
one (1) year or two (2) year time frame, as the case may be, unless the parties
agree in writing to extend such time frame (the parties shall discuss in such
event, factors including but not limited to the necessity to obtain approval of
Product for its target indication(s)).

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 10 of 56

<PAGE>

2.8 If an NDA or equivalent ex-U.S. regulatory approval in the European Union
(Marketing Authorization Application via the Centralized Procedure or marketing
approvals for the member countries of the European Union via the mutual
recognition procedure) for the Product not obtained within three (3) years of
Vanda's or its Affiliate's or Sub-licensee's filing of an NDA or such other
equivalent ex-U.S. filing, and such failure is solely due to circumstances
within Vanda's reasonable control, then the parties shall discuss the reasons
and proposed remedies (or such failure in good faith; provided, however, that if
the parties are unable to agree on any such remedies, Novartis shall have the
right to terminate the sublicense granted by this Sublicense Agreement, but only
with respect to the United States or the European Union where such approval was
not obtained, unless the parties agree in writing to extend such time frame. If,
however, Novartis determines that such failure is due to circumstances beyond
the reasonable control of Vanda (including without limitation delays on the part
of the regulatory agencies), the three (3) year period shall be extended to take
into account such circumstances, the duration of any such extension to be
mutually agreed.

2.9 Subject to the provisions of Section 2.9(d), Novartis shall not be obligated
to refund any up front license fees and milestone payments paid by Vanda with
respect to any country(ies) which cease to be included within the Territory, and
in the event that (i) Novartis or its Affiliate(s) or Sub-licensee(s) elects to
commercialise the Product or Compound in such country(ies) and (ii) Vanda, its
Affiliate(s) or Sublicensee(s) has an NDA filing in the United States or an
equivalent filing in the European Union, then in consideration for the use of
any IND, NDA or other governmental approval or associated developmental work
held or owned by Vanda related to the Compound or Product:

(a) At Novartis' request, and subject to Sections 6.3 and 11.5 hereof, Vanda
shall license or otherwise make available under applicable law the benefit of
such approvals or work to Novartis or an Affiliate or Third Party designated by
Novartis (which third party could be HMRI or Titan), who shall thereafter have
the rights to develop, register, manufacture, market and sell the Compound and
Product in such country(ies) utilizing such approvals or work, and Novartis (or
such Affiliate or Third Party) shall pay to Vanda a royalty to be negotiated in
good faith at the time that Novartis exercises such option, on Net Sales of the
Product by Novartis or its designees in such country to equitably recognize the
value added by Vanda to the Compound and/or Product through its development
efforts. Such royalty shall not be greater than [*] percent ([*]%) on net sales
of Product by Novartis or its

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 11 of 56

<PAGE>

designees. Upon expiration of the Patent in such country, only the royalty paid
to Vanda for the use of the Vanda trademark under Section 2.5 shall be paid to
Vanda for so long as such trademark is utilized. If a trademark license has not
been granted to HMRI, Titan or Novartis in such country, no royalty shall be
paid to Vanda upon the expiration of the Patent.

(b) Novartis shall share [*] with Vanda any up front license fees, milestone
payments or other payments such as prepaid royalties received from a Third Party
in connection with the exercise of such option only. If Vanda has not paid to
Novartis the up front license fee and all of the milestone payments provided for
in Sections 3.1(a) through (c), then Vanda's share of the amount shall be
multiplied by a fraction, the numerator of which is equal to the total of the
payments that have been made by Vanda to Novartis under Sections 3.1(a) through
(c), and the denominator of which is equal to the total of the payments that
Vanda otherwise would have been required to pay to Novartis under Sections
3.1(a) through (c) had the sublicense not been terminated.

(c) Notwithstanding anything contained herein to the contrary, Novartis shall
not be required to pay to Vanda a royalty on sales of the Product that, when
added to the royalty payments for a license under the Vanda trademark payable
under Section 2.5, exceeds in the aggregate [*] percent ([*]%).

(d) If the circumstances leading up to the termination of the Sublicense
Agreement pursuant to Section 2.8 are due to any misrepresentations, omissions
(of information owned or controlled by Novartis or its Affiliates; as of the
date hereof) or falsifications with respect to such Know-How, information or
data or fraud by Novartis or its Affiliates, then subject to the following
sentence, Novartis shall repay to Vanda, within ninety-five (95) days of such
termination, that portion of the up front license fee and milestone payments
Novartis had received from Vanda up to the date of such termination. In the
case of misrepresentations, omissions (of information owned or controlled by
HMRI, Titan or their Affiliates as of the date hereof) or falsifications with
respect to such Know-How, information or data or fraud only by HMRI, Titan or
their Affiliates, and a termination of the HMRI Agreement pursuant to Section
2.5 of the HMRI Agreement, Novartis shall be obligated to make the foregoing
repayments to Vanda if, and only if, Titan has repaid the up front license fee
and milestone payments to Novartis under Section 2.9(d) of the Titan Agreement.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 12 of 56

<PAGE>

2.10 In the event that Vanda or a Sublicensee intends to seek a co-promotion or
co-marketing partner for the Product in the United States, Vanda shall notify
Novartis thereof in writing. Novartis shall then notify Titan thereof, and HMRI
shall have a right of first negotiation with Vanda or the Sublicensee on such a
collaboration. If HMRI exercises its right of first negotiation, then HMRI and
Vanda or the Sublicensee shall negotiate in good faith for a period of ninety
(90) days from the date of notification by Novartis to HMRI. If the negotiating
parties are unable to enter into a separate definitive written agreement
regarding such collaboration by the end of such ninety (90) day period, first
Novartis and then Titan will have the right to negotiate with Vanda in good
faith for a single period of ninety (90) days. In the event that Vanda or its
Sublicensee is unable to enter into a separate definitive written agreement
regarding such collaboration by the end of such ninety (90) day period with
Novartis or Titan, Vanda or the Sublicensee shall be free to enter into a
collaboration with any Third Party subject to all other terms of this Sublicense
Agreement and shall have no further obligation to negotiate with HMRI. For the
purposes of this Section 2.10, the term "co-promotion or co-marketing
partner" will not include an independent contract field sales force that may be
engaged by Vanda or a Sublicensee.

3. PAYMENTS AND ROYALTIES.

3.1 As consideration for the sublicenses granted to Vanda by Novartis under this
Sublicense Agreement, Vanda shall make the following payments to Novartis:

(a) An up front license fee of Five Hundred Thousand United States Dollars
(U.S.$500,000) shall be paid by Vanda to Novartis in cash within ten (10)
business days of both parties' execution of this Sublicense Agreement.

(b) A first development milestone payment of [*] be payable by Vanda to Novartis
one time only upon [*] for the Product in the Field [*]. As used in this
Section, [*].

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 13 of 56

<PAGE>

Such milestone payment shall be paid in cash by Vanda directly to Novartis
within seven (7) business days of the date of [*]. The [*] payment provided for
herein shall, unless otherwise expressly provided for herein, be non-refundable.

(c) A second development milestone payment of [*] which shall be payable one
time only by Vanda to Novartis on [*].

(d) Vanda shall notify Novartis in writing thirty (30) business days prior to
Vanda's estimated achievement of each milestone event described in Sections
3.1(b) and 3.1(c)(i) above and Vanda shall make each such payment within seven
(7) business days of the achievement of the milestone event for which such
payment is due.

3.2 (a) Unless Novartis instructs Vanda in writing otherwise, all cash payments
by Vanda to Novartis (including, without limitation, up front payments,
milestone payments, and royalties) shall be made by bank wire transfer as
follows:

Bank: [*]

Swift: [*]

Correspondent Bank for USD: [*]

USD Account Novartis AG, Basel / Switzerland: [*]

USD Account Novartis Pharma AG, Basel / Switzerland: [*]

(b) At least two (2) business days prior to the planned wire transfer to either
of the above accounts, Vanda shall notify Novartis of the amount and date the
cash shall be transferred.

(c) In the event of a late payment hereunder by Vanda to Novartis, Vanda shall
pay to Novartis interest [*] ([*]%) on the outstanding balance until such
balance, including interest, is paid in full to Novartis. The acceptance of such
late

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 14 of 56

<PAGE>

payment shall act as a waiver of any rights Novartis may have hereunder due to a
breach by Vanda relating solely to such payment being made late.

3.3 As consideration for the sublicense granted to Vanda in this Sublicense
Agreement, Vanda shall pay to Novartis, in those countries where, and for the
period, Patents claiming a priority date of May 19, 1989 and December 29, 1989
or Patents owned by Novartis AG in a particular country in the Territory for
which a patent had been granted validly claiming Iloperidone or the manufacture,
formulation or the use thereof for use in the Field:

(a) [*] per cent ([*]%) royalty on annual Net Sales of the Product of Vanda, its
Affiliates' and Sublicensees' annual Net Sales of the Product in the Territory.

(b) Vanda shall also pay to Novartis the following milestone payments:

<TABLE>
<CAPTION>
Net Sales Milestone      Milestone payment from Vanda to Novartis
-------------------      ----------------------------------------
<S>                      <C>
(A) Achievement of [*]                      [*]

(B) [*]                                     [*]

(C) [*]                                     [*]
</TABLE>

No [*] shall be payable by Vanda within one calendar year. In the event that a
[*] becomes due and payable [*]. Milestone (C) shall be payable at the earliest
on [*].

3.4 (a) In order to spread royalty payments hereunder over a sufficient period
of time, in each of those countries in the Territory where the Patents claiming
a priority date of May 19, 1989 and December 29, 1989 or Patents owned by
Novartis AG in a particular country for which a patent had been granted validly
claiming Iloperidone or the manufacture, formulation or use hereof for use in
the Field have expired, Vanda's obligations to pay royalties for use of Patents
in such country shall cease, and Vanda and/or any of its Sublicensees shall pay

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 15 of 56

<PAGE>

directly to HMRI a royalty for Know-How not relating to manufacturing (whether
or not such Know-How continues as a valid intellectual property right or is in
the public domain) of [*] percent ([*]%) on Vanda's, its Affiliates' and any
Sublicensees' annual Net Sales of the Product in each such country for a period
of ten (10) years after the expiration of the final remaining Patent claiming a
priority date of May 19, 1989 and December 29, 1989 or Patents owned by Novartis
AG in each such country. After the end of such ten (10) year period, no further
royalties arising from sales of the Product in such country shall be due to HMRI
and Vanda shall be entitled to continue to use the Know-How on a fully-paid,
irrevocable basis in accordance with Section 10.3.

(b) In the event that a Third Party's generic version of Iloperidone is actively
marketed in a process patent country (that is, any country in which the only
protection in relation to processes for the manufacture of Iloperidone has been
obtained and not protection for Iloperidone as a new chemical entity per se) in
the Territory where a Patent(s) has been granted validly claiming Iloperidone or
the manufacture, formulation or use thereof for use in the Field exists, then
subject to Sections 3.4(c) and (d) below, the royalty rate that Vanda shall pay
to Novartis on Vanda's or its Affiliate's or Sublicensees annual Net Sales of
the Product in that process patent country shall be [*] percent ([*]%) until
such Patent(s) expires, provided; (i) Vanda has obtained, or has made every
effort to obtain, the maximum allowable period of exclusivity to which it is
entitled based on the Product's registration data in that process patent country
to the extent such exclusivity in available; and (ii) The parties in accordance
with Article 8 of this Sublicense Agreement, will implement an appropriate
strategy for addressing the commercialization of Iloperidone by said Third
Party. Unless otherwise agreed to by the parties, Vanda shall at its sole cost
be obligated to diligently enforce the Patent(s) until there is a binding,
unappealable judicial determination as to whether the manufacture, formulation
or use of such generic version of Iloperidone infringes Patent(s) or until it is
demonstrated to the satisfaction of both Parties that such Patent(s) are not
being infringed in such country.

(c) If it is demonstrated to the satisfaction of both Parties or the binding
unappealable judicial determination under Section 3.4(b)(ii) holds that
Patent(s) are not being infringed in such process patent country, the royalty
rate that Vanda shall pay to Novartis on Vanda's or its Affiliate's or
Sublicensee's annual Net Sales of Product in that process patent country shall
continue to be [*] percent ([*]%) until such Patent(s) expires.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 16 of 56

<PAGE>

(d) If the binding, unappealable judicial determination under Section
3.4(b)(ii) holds that Patent(s) are being infringed in such process patent
country, Vanda shall take reasonable steps to have enforced such determination.
If as a result, the commercialization of Iloperidone by the Third Party in that
country is discontinued:

     (i) the royalty rate(s) that Vanda shall pay to Novartis on Vanda's or its
     Affiliate's or Sublicensee's annual Net Sales of the Product in that
     process patent country shall be, commencing on the later of: (A) the date
     such binding, unappealable judicial determination is rendered, and (B) the
     date (if any) specified in such determination that commercialization of
     such Third Party generic version of the Product is to be discontinued,
     those royalty rates provided for in Section 3.3 until such Patent(s)
     expires; and

     (ii) Vanda shall repay to Novartis, within thirty (30) days after the later
     of: (A) the date such binding, unappealable judicial determination was
     rendered, and (B) the date (if any) specified in such determination that
     commercialization of such Third Party generic version of the Product is to
     be discontinued, an amount equal to the difference between the royalties
     that Vanda would have paid to Novartis under Section 3.3, and the amount of
     royalties that Vanda actually paid to Novartis at the [*] percent ([*]%)
     rate, for the period commencing on the date the royalty rate for that
     process patent country was reduced to [*] percent ([*]%) pursuant to
     Section 3.4(b), and ending on the later of: (A) the date such binding,
     unappealable judicial determination was rendered, and (B) the date (if any)
     specified in such determination that commercialization of such Third Party
     generic version of the Product is to be discontinued.

(e) After a Patent(s) in any process patent country expires, Vanda and/or its
Sublicensee shall pay directly to Novartis royalties as provided for in Section
3.4(a).

3.5 As consideration for the sublicense granted to Vanda under this Sublicense
Agreement in those countries in the Territory for which (a) a Patent application
for the Compound or Product is pending or (b) no Patent application has been
filed or (c) Patents have been abandoned or been held invalid or unenforceable
by a decision of a court or tribunal of competent jurisdiction from which no
appeal is or can be taken (collectively, "Non-Patent Countries"), Vanda shall
pay to Novartis, on a country-by-country basis, a [*] percent

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 17 of 56

<PAGE>

([*]%) royalty for Know-How not relating to manufacturing (whether or not such
Know-How continues as a valid intellectual property right or is in the public
domain) on Vanda's, its Affiliates' and any Sublicensees' annual Net Sales of
the Product in the Non-Patent Countries for a period of five (5) years from the
date of the first commercial sale of the Product in each such country by Vanda,
its Affiliates or Sublicensees. After the end of such five (5) year period, no
further royalties arising from the sales of the Product in such country shall be
due. However, with respect to Section 3.5(a) or (b), if at any time during or
after such five (5) year period a Patent for Compound or Product is issued in
such country, subject to Section 3.4, Vanda shall pay to Novartis, from the date
the Patent was issued, the same royalties as provided for in Sections 3.3(a) and
(b) above. Upon expiration of Vanda's obligation to pay a royalty under such
Patent, notwithstanding Section 3.4, a [*] percent ([*]%) royalty for Know-How
not relating to manufacturing (whether or not such Know-How continues as a valid
intellectual property right or is in the public domain), on Net Sales of the
Product in such country, shall be paid by Vanda and/or any of its Sublicensees
directly to HMRI for a period of five (5) years after which Vanda shall be
entitled to continue to use the Know-How on a fully-paid, irrevocable basis in
accordance with Section 10.3.

4. COMPULSORY LICENSES AND THIRD PARTY LICENSES

4.1. (a) in the event that during the term of this Sublicense Agreement a
governmental agency in the Territory grants or compels HMRI and/or Titan and/or
Novartis to grant a license to any Third Party for the Compound or Product in a
country(ies), it is the intent of the parties that Vanda not be placed at a
competitive disadvantage as a result of a lower royalty rate being granted to a
Third Party compulsory licensee. Therefore, in the event that Novartis, Titan or
HMRI is compelled to grant a license to a Third Party, Novartis, Titan and HMRI
will meet to discuss in good faith equitable arrangements, which could include
adjustments to Vanda's original royalty rates in Section 3.3 of this Sublicense
Agreement which are to be paid on Net Sales of Product in such country, to
accomplish the intent of Novartis and Vanda set forth above. In such
discussions, consideration will be given to Novartis' obligations to HMRI and
Titan under Section 4.l (d) of the Titan Agreement.

(b) If a governmental authority in a country in the Territory imposes a maximum
royalty rate, such that lower royalty rates than would otherwise apply under
this Sublicense Agreement are mandated in such country, then the royalty rates
provided for herein shall be reduced to

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 18 of 56

<PAGE>

equal such lower rates for sales of the Product in such country for the period
such lower royalty rate is required by any governmental authority and shall
cease when Vanda's royalty payment obligations cease under this Sublicense
Agreement.

4.2 If, during the term of this Sublicense Agreement, HMRI and Vanda agree that
patent(s) of a Third Party exists in the Territory covering the manufacture, use
or sale of the Compound or Product, and if it should prove, in the reasonable
judgment of Vanda and HMRI, impractical or impossible for Vanda or its
Affiliates or Sublicensees to continue the activity or activities sublicensed
hereunder in the Field without obtaining a royalty-bearing license from such
Third Party under such patent(s) or if Vanda and HMRI otherwise agree it is
desirable for HMRI to acquire any Third Party patent or license in connection
with the development or manufacture of Compound or Product covered by Patents in
the Territory, then in either case the provisions of Section 8.8(c) shall apply.

4.3 If, after attempting in good faith to resolve the issue relating to
licensing Third Party patents in Section 4.2 between themselves, Vanda and HMRI
are unable to agree within ninety (90) days as to whether it is impracticable or
impossible for Vanda, its Affiliates or Sublicensees to continue the activity or
activities sublicensed hereunder without obtaining a royalty-bearing license
from a Third Party, the issue shall be submitted to a disinterested, competent
and experienced patent attorney reasonably acceptable to both Vanda and HMRI for
resolution. If Vanda and HMRI cannot agree on the selection of such patent
attorney, then each party shall select a patent attorney and the selected patent
attorneys shall select a mutually acceptable patent attorney who will determine
whether such Third Party rights materially inhibit Vanda's ability to
manufacture, distribute or sell the Compound or Product. The compensation to,
and expense of such patent attorney shall be borne by the party whose position
is not upheld by such patent attorney (that is, for example, if the patent
attorney determines that such Third Party rights do not materially inhibit
Vanda's ability to manufacture, distribute or sell the Compound or Product, then
the costs of such patent attorney shall be borne by Vanda).

5. DEVELOPMENT

5.1 Upon the signing of this Sublicense Agreement, Vanda shall have full legal
and financial responsibility for all costs that are incurred and all activities
that are undertaken after the


                                  Page 19 of 56

<PAGE>

signing of this Sublicense Agreement, which are related to development, safety
and required periodic reporting to the FDA and equivalent ex-U.S. regulatory
agencies, marketing, regulatory approvals, price registrations, and other
activities required by Vanda or its Sublicensee(s) (or their respective agents
or distributors) to obtain appropriate government approvals for, and to
commercialize, the Compound and Product in the Territory. Other than as
expressly provided for in Section 5.4, Vanda shall not assume, nor shall Vande
be liable for, any costs or activities (whether scientific, financial or
otherwise) relating to the Compound or Product that were incurred or undertaken
prior to the signing of this Sublicense Agreement (including without limitation
any costs, expenses, damages, losses, fines, penalties or the like that may be
awarded or assessed after the signing of this Sublicense Agreement, but which
arise out of events and activities that occurred prior to the signing of this
Sublicense Agreement).

5.2 Provided that the Affiliates, Sublicensees and other Third Parties agree to
substantially the same terms of confidentiality in Section 6.4 hereof, Vanda may
appoint such Affiliates, Sublicensees(s) and other Third Parties to perform any
and all development activities necessary to obtain government approvals for the
Product in the Territory. The appointment of any Sublicensee shall require
HMRI's prior written consent, which consent shall not be unreasonably withheld.

5.3 Vanda shall, in a manner consistent with the effort Vanda devotes to its own
products having the same or similar potential value as Product, exercise its
Commercially Reasonable Efforts and diligence in conducting clinical trials and
commercializing the Product alone or in collaboration with a Third Party, and in
undertaking those investigations and actions required to obtain appropriate
governmental approvals to manufacture the Compound and market the Product in the
Territory. All such activity shall be undertaken at Vanda's expense. Novartis
shall arrange with HMRI to provide assistance or consultation at Vanda's expense
in support of the development of the Compound or Product, but HMRI in its
discretion may limit such assistance and consultation.

5.4 The parties further agree that:

(a) Novartis will be informed by Vanda on a timely and regular basis of the
development, registration and commercialisation of the Compound and Product in
the Territory, and will


                                  Page 20 of 56

<PAGE>

have an opportunity to regularly meet with Vanda and provide input into the
development and registration process, and

(b) all of Novartis' contractual obligations to Third Parties involved in the
development and registration process for the Compound and Product (including
Contract Research Organizations (CROs) existing as of the date of this
Sublicense Agreement, which CROs are identified in APPENDIX E), will be
considered by Vanda to the extent they are not inconsistent with Vanda's
Standard Operating Procedures.

(c) Vanda shall be solely responsible for the negotiation of contracts with any
CROs and other organisations it desires to work on development activities
relating to the Compound and/or Product and Vanda shall bear all legal and
financial responsibility under such contracts.

5.5 Any inventions or discoveries or improvements which arise from Vanda's, its
Affiliates' or Sublicensees work relating to the development and/or manufacture
of the Compound and/or Product shall be owned by Vanda, but shall be licensed to
HMRI, Titan and Novartis at their option on a worldwide, non-exclusive,
perpetual basis, at a license fee and/or royalty to be negotiated at such time.
In the case of any inventions or discoveries or improvements arising in areas
outside of the original field, which was defined in the HMRI Agreement and the
Titan Agreement, shall be owned by Vanda, but shall only be licensed to HMRI, at
HMRI's option on a worldwide, non-exclusive, perpetual basis, at a license fee
and/or royalty to be negotiated at such time. Notwithstanding anything to the
contrary in this Sublicense Agreement, in the event that this Sublicense
Agreement between Novartis Pharma AG and Vanda Pharmaceuticals, Inc. expires or
terminates, in its entirety or with respect to any country, (except as a result
of material breach of the Agreement by Novartis), any inventions or discoveries
or improvements which arise from Vanda's, its Affiliates' or Sublicensees' work
relating to development and/or manufacture of the Compound and/or Product (the
"Vanda IP") shall be disclosed to HMRI and be owned by and become the property
of HMRI (or assignees or successors, as the case may be), but shall be licensed
to Titan under Section 2.1(a) of the HMRI- Agreement and subsequently to
Novartis under the Titan Agreement. Vanda shall promptly undertake any and all
actions necessary to effectuate such ownership in and assignment to HMRI. If the
Vanda Sublicense Agreement expires or terminates with


                                  Page 21 of 56

<PAGE>

respect to a particular country, then the requirements of this Section 5.5 and
Aventis' rights to the Vanda IP shall be limited to such country.

5.6 deleted.

5.7 In addition to that which is required under Section 5.4(a), Vanda shall
provide to Novartis regular written reports at least every six (6) months
setting forth significant developments and improvements, including the status
and progress of the development and/or registration activities, that affect the
Compound or Product.

5.8 Vanda, or its Sublicensees, shall promptly advise Novartis in writing upon
the submission and filing for government regulatory approval to manufacture and
market the Product, and upon the receipt of government regulatory approval to
market the Product, in each case in each country in the Territory, and shall
commence marketing the Product in such country in accordance with Section 5.3.

5.9 Subject to applicable laws and regulations, labeling on all Product sold by
or on behalf of Vanda pursuant to this Sublicense Agreement, and all
advertising, marketing and promotional materials used in connection therewith,
will identify Novartis as the licensor of the Product.

5.10 If at any time during the term hereof a product is developed by Vanda or
any of its Affiliates or Sublicensees, which product contains the Compound and
one or more other pharmaceutically active ingredients for use in the Field (a
"Combination Product"), Novartis shall negotiate in good faith with Titan an
amendment to the Titan Agreement, which amendment will provide, inter alia for
how royalties to be paid by Novartis to Titan for Net Sales of such Combination
Product will be calculated and for how long such royalties shall be paid. After
such amendment to the Titan Agreement has been executed by Novartis and Titan,
this Sublicense Agreement shall be similarly amended by Novartis and Vanda to
provide for such Combination Product.

6. EXCHANGE OF INFORMATION AND CONFIDENTIALITY.

6.1 Upon the signing of this Sublicense Agreement, Novartis shall deliver to
Vanda, all available Know-How, documents, information and data which is owned
or controlled by Novartis and its Affiliates, which may be reasonably expected
to assist Vanda in developing, registering, manufacturing and marketing the
Compound and Product in the Territory. After the execution of this Sublicense
Agreement, there shall be a sixty (60) day transition period


                                  Page 22 of 56

<PAGE>

during which Novartis shall provide, at its own cost, reasonable resources,
expertise, and documents to effectively transfer the Know-How and development
activity to Vanda. Banked DNA samples and or animal tissues treated with the
compound will only be made available to Vanda for further studies in accordance
with the protocols and informed consents set forth at the time of sample
acquisition provided however that no human tissue samples with identifiable
patient data will be transferred to Vanda. All raw data and individual clinical
and genetic data will be transferred to Vanda under a mutually agreed coding
schema, in order to protect patient confidentiality. All original identifiable
patient data will, however be provided to the FDA as part of the submission
package. If Vanda requires additional genotyping on existing samples, Novartis
will contract this work out, in accordance with the informed consents, on
Vanda's behalf and at Vanda's cost. If further DNA samples from past study
patients are desired, Vanda will revisit the sites and try to consent or
reconsent these patients for additional DNA sampling. Upon Novartis' receipt of
the up front license fee referred to in Section 3.1(a) hereof, Vanda and
Novartis each shall promptly provide written notification to the FDA that
Novartis assigns and that Vanda assumes sponsorship of the U.S. IND No. 36,827
(as specified in 21 CFR 314.72). Within ten (10) days after the date of such
written notification, Novartis shall transfer the U.S. IND for the Compound or
Product to Vanda. Until such transfer is made, Vanda shall have the right to
make reference to such Compound or Product owned or controlled by Novartis or
its Affiliates. Furthermore, upon Novartis' receipt of the upfront license fee
referred to in Section 3.1(a), Novartis shall arrange for the transfer to Vanda
of Canadian IND Control No. 27740.

6.2 Vanda shall have Exclusive use, subject to the terms of this Sublicense
Agreement and in particular Section 2.3, of all Know-How, documents,
information, data and material for the development, registration, manufacture
and marketing of the Compound and the Product for use in the Field in the
Territory. Novartis and its respective Affiliates shall keep confidential all
Know-How, documents, information and data in their possession or received from
or generated by or on behalf of Vanda that is not already in the public domain
relating to the Compound and Product regarding the use in the Field with the
same level of care that Novartis and its respective Affiliates use for their own
confidential information. Upon Novartis' request during the term of this
Sublicense Agreement, Vanda shall deliver to Novartis a copy of all such
information and data in a form to be mutually agreed upon, within thirty (30)
days after Novartis' request, it being understood and agreed that any and all
such information and data will be made available by Novartis to Titan, upon
Titan's request.

6.3 Subject to the confidentiality obligations of this Article 6, Vanda shall
make available and HMRI, Titan and Novartis shall be able to freely use Know-How
and documents, information and data relating to the Compound and/or Product
disclosed or generated by Vanda, its Affiliates and Sublicensees and
applications for government approvals (United States or


                                  Page 23 of 56

<PAGE>

European Union or Japan), reports on the status and progress of the development
of the Compound or the Product and the like in any country(ies) deleted from the
Territory and to which this Sublicense Agreement has been terminated pursuant to
the terms hereof.

6.4 During the period of time during which Vanda is obligated to pay royalties
hereunder, irrespective of any termination with respect to a particular country
or countries in the Territory, Vanda shall not reveal or disclose to a Third
Party or use for any purpose other than to perform its obligations herein any
Confidential Information (as defined below) without first obtaining the written
consent of Novartis, except as may be otherwise provided herein, or for securing
essential or desirable authorizations, privileges, licenses, registration or
rights from governmental agencies, or is required to be disclosed to a
governmental agency or is necessary to file or prosecute Patent applications
concerning the Compound or Product or to carry out any litigation concerning the
Compound or Product provided, however, that Vanda notifies Novartis in writing
in a reasonably sufficient time frame prior to making such disclosure that Vanda
intends to make such disclosures and the details thereof, and Vanda seeks
confidential treatment where available of such Confidential Information from
such governmental agencies. This confidentiality obligation shall not apply to
such information which is or becomes a matter or public knowledge through no
fault of Novartis, or is already in the possession of Novartis as evidenced by
written records, or is disclosed to Vanda by a Third Party having the right to
do so, or is subsequently and independently developed by employees of Novartis
or its Affiliates who had no knowledge of the Confidential Information. Vanda
shall take reasonable measures to assure that no unauthorised use or disclosure
is made by others to whore access to such information is granted. As used
herein, "Confidential Information" means, any confidential or proprietary
information of HMRI, Titan or Novartis or their Affiliates, including any
present or future formulas, research project, work in process, inventions,
procedures, development, scientific, engineering, manufacturing, marketing,
business or financial plan or records, products, sales, suppliers, customers, or
investors, whether such confidential or proprietary information is in oral,
written, graphic or electronic form (including all copies in whole or in part of
any of the foregoing) and which derives value from being known to the disclosure
or owner.

6.5 After transfer of the United States and Canadian INDs to Vanda under Section
6.1, Novartis and Vanda shall co-operate with respect to the exchange of adverse
event and safety information associated with Compound and Product, and such
information shall be coordinated by Vanda central clinical, safety and
epidemiology organisation. Details of the obligations of the parties with
respect to reporting such information to each other, and processing of this data
shall be covered in an addendum following execution of this Sublicense
Agreement.


                                  Page 24 of 56

<PAGE>

6.6 Nothing herein shall be construed as preventing Vanda from disclosing any
information received from Novartis to an Affiliate, Sublicensee, distributor,
contractor, agent, consultant, legal counselor other Third Party involved in the
development, manufacture, marketing, promotion or sale of the Compound or
Product, provided that such Affiliate or Sublicensee or other Third Party has
undertaken a similar obligation of confidentiality with respect to the
Confidential Information.

6.7 In the event that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or receiver, assumes partial or
complete control over the assets of Vanda based on the insolvency or bankruptcy
of Vanda, Vanda shall promptly notify the court or other tribunal (i) that
Confidential Information received from Novartis remains the property of HMRI,
Titan or Novartis, or their respective Affiliates, as the case may be, and (ii)
of the confidentiality obligations under this Sublicense Agreement. In addition,
Vanda shall, to the extent permitted by law, take all steps reasonably necessary
or desirable to maintain the confidentiality of the Confidential Information of
HMRI, Titan or Novartis, as the case may be, and to ensure that the court, other
tribunal or appointee maintains such information in confidence in accordance
with the terms of this Sublicense Agreement.

6.8 No public announcement or other disclosure to a Third Party concerning the
existence of or terms of this Sublicense Agreement shall be made, either
directly or indirectly by either party to this Sublicense Agreement, except as
may be legally required, without first obtaining the approval of the other
party, which approval shall not be unreasonably withheld, and shall be given
within a reasonable time. The party desiring to make any such public
announcement or other disclosure shall provide the other party with a written
copy of the proposed announcement or disclosure in sufficient time prior to the
proposed public release, to allow such other party to comment upon the nature,
content and timing of such announcement or disclosure, prior to the proposed
public release. Notwithstanding the foregoing, Vanda shall be permitted to refer
to this Sublicense Agreement in presentation to prospective investors.

6.9 Neither party shall submit for written or oral publication any manuscript,
abstract or the like which includes Know-How, data or other information
generated and/or provided by Novartis or Vanda pursuant to this Sublicense
Agreement without first obtaining the prior written consent of the party
generating or providing such information, which consent shall not be
unreasonably withheld. The contribution of each party shall be noted in all
publications or presentations by acknowledgment or co-authorship, whichever is
appropriate.

7. NOVARTIS SUPPLY OF COMPOUND AND PRODUCT TO VANDA.

7.1 Novartis shall supply Compound and Product to Vanda under the following
conditions:


                                  Page 25 of 56

<PAGE>

(a) Within sixty (60) days after the Effective Date of this Sublicense Agreement
as agreed to by the parties in good faith, Novartis will, at Vanda's cost,
arrange for the transfer to Vanda, to a single site to be designated by Vanda,
all quantities of milled Compound available to it as of the Effective Date of
this Sublicense Agreement.

(b) Title to, and risk of loss with respect to, all Compound and the Product
supplied by Novartis to Vanda under this Section 7.1 shall pass to Vanda upon
the receipt of such Compound and Product by Vanda or its designee at its point
of delivery. Novartis shall not be liable for any loss of such Compound and/or
Product except where such loss is the result of Novartis negligence or willful
misconduct.

(c) Novartis shall provide to Vanda the most recent certificate of analysis for
any shipment of Compound or Product.

(d) Novartis makes no representation or warranty that Compound and Product
supplied by it to Vanda for clinical trials will conform to the IND
specifications therefore as well as all laws and regulatory requirements,
including current Good Manufacturing Practices applicable to the Compound and
Product when used in clinical trials in accordance with the IND.

7.2 Novartis shall provide information and assistance to Vanda with respect to
the Compound and Product as follows:

(a) Within sixty (60) days after the full execution and delivery of this
Sublicense Agreement, Novartis shall deliver to Vanda any and all Know-How,
documentation, data and other information owned or controlled by Novartis and
its Affiliates, that Vanda may reasonably require for the manufacture of the
Compound and Product. Such information shall include without limitation the
specifications for the Compound and Product and methods of analysis for testing
the Compound and Product, as currently described within the IND regulatory
documentation, including Chemistry-Manufacturing/Controls (CMC) information
amendments and the technology transfer file.

(b) Novartis shall make reasonable commercial efforts to arrange for HMRI to
provide to Vanda or its designated Third Party assistance for the transfer of
manufacturing technology, through documentation, consultation and face-to-face
meetings, to enable Vanda or such Third Party to proceed with development of
commercial-scale manufacturing. If requested by Vanda or such Third Party,
Novartis shall visit the designated commercial manufacturing facility, with the
limitation of three (3) visits, not to exceed a total of ten (10) business days,


                                  Page 26 of 56

<PAGE>

for which Vanda shall bear all the costs of reasonable travel and other
out-of-pocket expenses.

7.3 Novartis represents and warrants that the specifications for the Compound
and Product are consistent with those set out in the INDs sponsored by Novartis.

7.4 Upon expiration or termination of this agreement, Vanda shall return to
Novartis, all unused Compound or Product supplied by Novartis hereunder.

8. PATENT PROSECUTION; MAINTENANCE AND EXTENSION; INFRINGEMENT

8.1 HMRI shall be responsible for the filing, prosecution (including
oppositions) and maintenance of the Patents excluding Novartis Patents
(hereinafter "HMRI-Patents") at HMRI's expense. For so long as the-license
grants set forth in Article 2 remain in effect, HMRI agrees to file and
prosecute and maintain the HMRI-Patents in the Territory, provided that the
foregoing is subject to HMRI's reasonable business judgment. Novartis shall keep
Vanda informed, to the same extent HMRI and/or Titan keep Novartis informed, of
important issues relating to the preparation, filing, prosecution and
maintenance of such HMRI-Patent applications and HMRI-Patents. Vanda, through
Novartis, shall have the right to comment on HMRI's preparation, filing,
prosecution and maintenance of HMRI-Patent applications and HMRI-Patents, and
HMRI shall give due consideration to Vanda's comments, but HMRI shall make all
decisions regarding the same.

8.2 If HMRI elects not to seek patent protection in countries listed in APPENDIX
F or to maintain patent protection on HMRI-Patents listed in APPENDIX A in any
country in the Territory to the extent that HMRI-Patents claim the Compound or
the Product (or formulations, use or manufacture thereof), Vanda shall have the
right, at its option and at HMRI's expense, which expense must be approved in
advance by HMRI (approval which shall not be unreasonably withheld), to file,
prosecute (including oppositions) and maintain any such HMRI-Patent applications
and HMRI-Patents in HMRI's name, and any HMRI-Patent issued therefrom shall be
owned by HMRI. Novartis shall advise Vanda of HMRI's decision) not to seek or
maintain patent protection in a reasonably timely manner. In the event that a
HMRI-Patent is issued covering the Compound or Product in any country in
Territory under the conditions of this Section 8.2, Vanda shall pay directly to
HMRI a [*] percent ([*]%) royalty on Net Sales of Product in such country, for a
period of five (5) years from the date of such patent issuance in such country,
in recognition of HMRI's Know-How and manufacturing rights and the right to make
and sell the Compound or Product in such

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 27 of 56

<PAGE>

country. Legal fees and expenses, as confirmed by HMRI, incurred by Vanda shall
be deducted from the royalty paid to HMRI.

8.3 Vanda shall be responsible for the filing, prosecution (including
oppositions) and maintenance of the Patents owned by Novartis (hereinafter
"Novartis-Patents") at Vanda's expense. Vanda agrees to file and prosecute and
maintain the Novartis-Patents in the Territory, provided that the foregoing is
subject to Vanda's reasonable business judgment. Novartis, shall have the right
to comment on Vanda's preparation, filing, prosecution and maintenance
of Novartis-Patent applications and Novartis-Patents, and Vanda shall give due
consideration to Novartis' comments. If Vanda elects not to maintain patent
protection on Novartis-Patents in any country, Novartis shall have the right, at
its option, to file, prosecute and maintain any such Novartis-Patent. Vanda
shall have the right but not the obligation to enforce Novartis-Patents against
Third Parties at its cost, and if Vanda does not act, Novartis may in its sole
discretion take such enforcement action as Novartis deems necessary.

8.4 Each of HMRI, Titan, Novartis and Vanda shall make available to the other,
its employees, agents, subcontractors or consultants (including its authorized
attorneys) to the extent reasonably necessary or appropriate to enable the
appropriate party to file, prosecute and maintain patent applications and
resulting patents subject to this Sublicense Agreement to the extent that
Patents claim the Compound or Product (or formulations, use or manufacture
thereof). Where appropriate, each of HMRI, Titan, Novartis and Vanda shall sign
or cause to have signed all documents relating to said patent applications or
patents at no charge to the other.

8.5 Novartis shall obtain all assignments or licenses, as applicable from the
patent holder of the Patents, to the same extent as Novartis is entitled to
receive such assignments or licenses from HMRI and Titan under the HMRI
Agreement as applicable, to provide Vanda with the same degree of exclusivity in
the Territory under the Patents as Novartis is granted by HMRI and Titan under
the Titan Agreement.

8.6 Promptly after it is notified by HMRI and Titan, Novartis shall notify
Vanda in writing of (a) the issuance of each HMRI-Patent, giving the date of
issue and patent number for each patent, and (b) each notice pertaining to any
HMRI-Patent which HMRI receives as patent owner pursuant to the Drug Price
Competition and Patent Term Restoration Act of 1984, or other similar laws now
or hereafter in effect which extend the Patent life, or pursuant to comparable
laws or regulations in other countries in the Territory. At HMRI's expense,
HMRI, Titan, Novartis and Vanda shall co-operate with each other in applying for
patent term extensions (including Supplementary Protection Certificates in
European Union member states) where applicable in any country of the Territory.
HMRI shall have full


                                  Page 28 of 56

<PAGE>

responsibility and authority in the decisions regarding filing for the foregoing
HMRI-Patent extensions at its own expense although Vanda, through Novartis,
shall be consulted and its opinions given due consideration in such
decision-making process. If HMRI elects not to pursue extension of any
HMRI-Patents, Vanda shall have the right (but not the obligation) to apply for
such extension in HMRI's name and at Vanda's expense, and HMRI shall reasonably
co-operate in the filing and procurement thereof.

8.7 Except as otherwise expressly provided in this Sublicense Agreement, under
no circumstances shall a party hereto, as a result of this Sublicense Agreement,
obtain any ownership interest in or other right to any technology, Know-How,
Patents, pending Patent applications, products, or biological material of the
other party, Titan or HMRI, including items owned, controlled, discovered,
invented or developed by the other party, Titan or HMRI, or transferred by the
other party, Titan or HMRI to that party, at anytime pursuant to this Sublicense
Agreement which is not a direct result of the study, Know-How and
experimentation of the Compound and Product.

8.8 Each of Vanda, Novartis, Titan and HMRI shall promptly, but in any event no
later than ten (10) business days after receipt of notice of such action, notify
the other in writing of any Patent nullity actions, any declaratory judgment
actions or any alleged or threatened infringement of Patents or misappropriation
of intellectual property comprising Patents, or if Vanda, HMRI, Titan or
Novartis, or any of their respective Affiliates or Sublicensees, shall be
individually named as a defendant in a legal proceeding by a Third Party
alleging infringement of a patent or other intellectual property right of such
Third Party as a result of the manufacture, production, use, development,
marketing, selling or distribution of the Compound or Product, or of any
information or notification regarding the Patents.

8.9 HMRI shall have the first right to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party alleging infringement described in Section 8.8. In the event HMRI elects
to do so, Vanda will co-operate with HMRI and its legal counsel, join in such
suits as may be brought by HMRI, and be available at HMRI's reasonable request
to be an expert witness or otherwise to assist in such proceedings and at
HMRI's expense. HMRI will co-operate with Vanda and its legal counsel and keep
Vanda and its counsel reasonably informed at all times as to the status of
HMRI's response or defense.

8.10 In the event that HMRI elects to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party claiming infringement described in Section 8.8 hereof, then: (a) legal
fees and other costs and expenses of HMRI associated with such response or
defense shall be paid by HMRI; (b) legal fees and other


                                  Page 29 of 56

<PAGE>

costs and expenses associated with such response or defense incurred by Vanda at
HMRI's request, shall be paid by HMRI; (c) the costs of acquiring Third Party
patents or licenses and any settlement, court award, judgment or other damages
shall be paid by HMRI to such Third Parties out of royalties projected to be
received from Vanda (through Titan or Novartis); provided, however, HMRI shall
not be obligated to pay for any patents or licenses for uses of the Compound or
Products not disclosed in the Patents as of the date of the execution of the
HMRI Agreement; and (d) any amounts recovered from Third Parties in connection
with such response or defense shall be applied [*] percent ([*]%) to Vanda
(through Titan and Novartis), and [*] percent ([*]%) to HMRI, subject first to
reimbursement of expenses of HMRI, Novartis, Vanda and Titan.

8.11 In the event that HMRI elects not to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party alleging infringement described in Section. 8.8 hereof or HMRI abandons
any such action, Novartis shall notify Vanda promptly after receiving
notification from HMRI or Titan of such actions, challenges, infringements,
misappropriations, proceeding or HMRI's decision to abandon any such action. In
such event, Vanda shall have the option to respond, defend or prosecute such
action at Vanda' sole cost, provided that HMRI shall co-operate with and provide
assistance to Vanda at HMRI's expense. All amounts recovered from any Third
Party shall be applied [*] percent ([*]%) to Vanda and [*] percent ([*]%) to
HMRI, subject first to reimbursement of expenses of HMRI, Vanda, Novartis and
Titan.

8.12 In the event that HMRI and Vanda mutually agree that it is desirable for
HMRI to acquire any Third Party patent or license in connection with the
development or manufacture of the Compound or Product covered by the
HMRI-Patents in the Territory then the costs of acquiring such Third Party
patent or license shall be paid by HMRI to such Third Parties out of royalties
received from Vanda (either directly or through Titan and Novartis).

8.13 Vanda recognises that HMRI has reserved certain rights in the HMRI-Patents
set forth in APPENDIX A and that there may be a legitimate dispute between the
parties whether a legal action should be brought against a Third Party which
could affect HMRI's reserved rights under those HMRI-Patents and Vanda's
sublicense rights under this Sublicense Agreement. In the event that there is a
dispute between Vanda and HMRI regarding whether there is an infringement of
HMRI-Patents by a Third Party and therefore whether a legal action should be
initiated, Vanda and HMRI shall submit the issue to a disinterested, competent
and experienced patent attorney reasonably acceptable to Vanda and HMRI to
determine whether or not there is an infringement and legal actions should be
taken. If Vanda and HMRI cannot agree on the selection of such a patent
attorney, then Vanda and HMRI shall each select a patent attorney and those
selected patent attorneys shall select a mutually acceptable patent

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 30 of 56

<PAGE>

attorney. That selected patent attorney shall determine whether or not there is
an infringement and legal action should be taken and then Vanda and HMRI may
decide whether or not to initiate a legal action as described by this Article 8.
The compensation to, and expenses of, such patent attorney shall be borne by the
losing party.

9. STATEMENTS AND REMITTANCES.

9.1 Vanda shall keep, and require its Affiliates and Sublicensees to keep
complete and accurate records of all Net Sales of the Product under the
sublicenses granted herein. HMRI and Novartis shall have the right, at their
expense, through a certified public accountant or like independent person
reasonably acceptable to Vanda, and following reasonable notice, to examine such
records under conditions of confidentiality during regular business hours during
the period of time during which royalties are due and payable hereunder and for
[*] thereafter; provided, however, that such examination shall not take place
more often than once a year and shall not cover such records for more than the
preceding [*]; and provided further, that such accountant shall report to
Novartis only as to the accuracy of the Net Sales computation and royalty
statements and payments. It is agreed that if this Sublicense Agreement is
terminated with respect to a particular country(ies), then Novartis' examination
rights shall continue with respect to sales of the Product in such country(ies)
only for a period of [*] after the termination of sublicense rights in that
country. Copies of all such accountant's reports shall be supplied to Vanda.

9.2 Within forty-five (45) days after the close of each calendar quarter, Vanda
shall deliver to Novartis a true accounting of all Product sold by Vanda, its
Affiliates and Sublicensees during such quarter and shall at the same time pay
all earned royalties due. Such accounting shall show Net Sales of Product on a
country-by-country and product-by-product basis and such other particulars as
are reasonably necessary for accounting of the royalties payable hereunder.

9.3 Any tax paid or required to be withheld by Vanda on account of royalties
payable by Vanda under this Sublicense Agreement shall be indicated on the
accounting described in Section 9.2 hereof and deducted from the amount of
royalties otherwise due. Vanda shall secure and send to Novartis or HMRI, as the
case may be, proof of any such taxes withheld and paid by Vanda. Any withholding
or other tax arising on or following permitted assignment of this Sublicense
Agreement by Vanda or a Sublicensee shall be for the account of and paid by
Vanda.

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 31 of 56

<PAGE>

9.4 Unless otherwise indicated herein, and subject to foreign exchange
regulations then prevailing, to the extent free conversion from local currency
to United States dollars is permitted, all payments and royalties payable under
this Sublicense Agreement shall be paid in cash in U.S. dollars by wire transfer
in accordance with Section 3.2 hereof. If governmental regulations prevent
remittances from a foreign country with respect to sales made in that country,
the obligation of Vanda to pay royalties on sales in that country shall be
suspended until such remittances are possible, but such royalties shall accrue
as accounts payable by Vanda to Novartis or HMRI, as the case may be. Novartis
or HMRI, as the case may be, shall have the right, upon giving written notice to
Vanda, to receive payment in that country in local currency.

9.5 Royalty payments and Net Sales shall be calculated on the basis of Vanda's
quarterly standard account of internal sales which represents the conversion of
all local currency sales for a calendar quarter into Swiss francs at the average
exchange rate: (as routinely derived via Vanda's' standard methodology) for such
calendar quarter in which the sales are recorded. The exchange rate between the
Swiss franc and the U.S. dollar for the quarterly royalty payments to Novartis
or HMRI (as the case may be) shall be the exchange rates published in the
Foreign Exchange column of The Wall Street Journal, New York edition, or other
qualified source mutually acceptable to the parties on the last business day of
the calendar quarter for which the royalties are being paid. Notwithstanding the
foregoing, if there is a difference between any amount that Vanda pays to
Novartis or HMRI (as the case may be) under Sections 3.3, 3.4 or 3.5, and the
amount that Novartis is required to pay to Titan under the Titan Agreement
(which difference arises as a result of using the method for calculating
royalties that are due and payable under this Section 9.5, and the method for
calculating such royalties under Section 9.5 of the Titan Agreement), the
shortfall or excess (as the case may be) in royalty payments made by Vanda under
this Section 9.5 shall be paid by Vanda to HMRI or Novartis (as the case may be)
in the case of a shortfall, and by Novartis to Vanda in the case of an excess
payment by Vanda to Novartis under Section 3.3 or 3.5.

10. TERM AND TERMINATION

10.1 (a) Vanda will have the right to terminate the sublicense for the Territory
or on a country-by-country basis for major problems associated with the Product
as reasonably determined by Vanda. For this purpose "major problems" are ones
which would substantially negatively impact the Product's chances for successful
development, registration and/or commercialization in the Territory or such
country, as applicable; and would include, but not be limited to, major safety
issues, lack of efficacy, unacceptable pharmaceutical properties or
extraordinary unforeseen competitive developments which, in each case, would
have the substantial negative impact referred to above.


                                  Page 32 of 56

<PAGE>

(b) In the event of termination in the entire Territory by Vanda pursuant to
this Section 10.1, Vanda shall, within thirty (30) days of such termination,
return to Novartis any and all information and data (including new information
and data) relating to the Compound and Product, whether generated by or on
behalf of Titan, Novartis, HMRI or Vanda, and make no further use thereof.
Additionally, in such event, this Sublicense Agreement shall terminate in its
entirety and the sublicense granted hereunder shall revert back to Novartis.
Novartis shall retain all up front license fees and milestone payments it had
received up to the date of termination if, and only if, termination was not due
to any fraud, misrepresentations, omissions or falsifications of information
with respect to such Know-How, information or data owned or controlled by HMRI,
Titan, Novartis or their Affiliates as of the date hereof in which case, to the
extent that Novartis has for its own part perpetrated a fraud,
misrepresentation, omission or falsification of information with respect to such
Know-How, information or data owned or controlled by it, Novartis shall repay to
Vanda, within ninety-five (95) days of such termination, that portion of the up
front license fee and milestone payments Novartis had received from Vanda up to
the date of such termination. In no event shall Novartis be liable to Vanda for
any misrepresentation, omission or falsification of information owned or
controlled by HMRI or Titan or their Affiliates.

(c) Novartis may terminate this Sublicense Agreement by giving Vanda three
months prior written notice in the event that the time period elapsing between
patient dosing in clinical trials is greater than eighteen (18) months or more
than twelve (12) months elapses between the grant of first marketing
authorization in the United States or a Major Market Country and the commercial
launch of the Product in that country.

10.2 In the event the development of the Compound and Product is terminated
altogether by Vanda on or before January 1, 2006, for reasons other than those
described in Section 10.1, then this Sublicense Agreement shall terminate in its
entirety and the sublicense granted hereunder shall revert back to Novartis.
Novartis shall retain all up front license fees it had received up to the date
of termination and Vanda shall also pay a [*] penalty payment to Novartis if,
and only if, termination was not due to any fraud, misrepresentations, omissions
or falsifications (of information owned or controlled by HMRI, Titan, Novartis
or their Affiliates with respect to Know-How, information or data).

10.3 Unless otherwise terminated, this Sublicense Agreement shall expire on a
country-by-country basis upon the expiration of Vanda's obligation to pay
royalties under this Sublicense Agreement in each such country. Expiration of
this Sublicense Agreement under this provision shall not preclude Vanda, its
Affiliates and Sublicensees from continuing directly

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 33 of 56

<PAGE>

or indirectly to manufacture the Compound and market and sell Product and to use
Know-How without further royalty payments.

10.4 In the event there is a change in the control of Vanda, Vanda shall give
Novartis thirty (30) days written notice of such event and that the development
and commercialisation of COMPOUND and PRODUCT will continue per the terms of
this Sublicense Agreement.

10.5 (a) If either party materially defaults in its performance of this
Sublicense Agreement and if such default is not corrected or if the party in
default is not exercising reasonably diligent efforts to cure such default
within ninety (90) days after receiving written notice from the other party with
respect to such default, or if such default is not correctable within ninety
(90) days then such other party shall have the right to terminate this
Sublicense Agreement at the end of such period in its entirety by giving written
notice to the party in default. In the event Vanda. materially defaults in its
performance under this Sublicense Agreement with respect to a particular
country, then, subject to Section 11.4 hereof, Novartis' right to terminate
shall be limited to termination of the sublicense granted hereunder in such
country only.

(b) if Novartis materially defaults in its performance of the Sublicense
Agreement, then Vanda shall have the right but not the obligation to correct or
cure such default in the place of Novartis at Vanda's' own cost and expense
within the ninety (90) day period provided for in Section 10.5 of the Titan
Agreement without prejudice to any other rights Vanda may have under this
Sublicense Agreement (including the right to recover amounts paid to Novartis),
provided that (i) Vanda notifies Novartis in writing of Vanda's election to do
so, and (ii) Vanda's correction or cure of such default does not increase
Novartis' liability under the Sublicense Agreement.

(c) It is agreed that a material default by Novartis under the Titan Agreement
shall be a material default by Novartis under this Sublicense Agreement.

10.6 Subject to applicable bankruptcy laws; either party may terminate this
Sublicense Agreement if, at any time, the other party shall file in any court
pursuant to any statute of the United States or of any individual state or
foreign country, a voluntary petition in bankruptcy or insolvency or for
reorganisation in bankruptcy or for an arrangement or the appointment of a
receiver or trustee of the party or of its assets, or if the other party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within ninety (90) days
after the filing thereof, or if the other party shall propose or be a party to
any dissolution, or if the other party shall make an assignment for the benefit
of creditors.


                                  Page 34 of 56

<PAGE>

(a) Without limitation, Vanda's rights under this Sublicense Agreement shall
include those rights afforded by 11 U.S.C. Section 365(n) of the United States
Bankruptcy Code and any successor thereto (the "Code"). If the bankruptcy
trustee of Novartis as a debtor or debtor-in-possession rejects this Sublicense
Agreement under 11 U.S.C. Section 365(n) of the Code, Vanda may elect to retain
its rights sublicensed from Novartis hereunder (and any other supplementary
agreements hereto) for the duration of this Sublicense Agreement and avail
itself of all rights and remedies to the full extent contemplated by this
Sublicense Agreement and 11 U.S.C. Section 365(n) of the Code, and any other
relevant sections of the Code and other relevant non-bankruptcy law.

11. RIGHTS AND DUTIES UPON TERMINATION.

11.1 Upon termination of this Sublicense Agreement (other than for Novartis'
breach), Novartis shall have the right to retain any suns already paid by Vanda
hereunder, and Vanda shall pay all sums accrued hereunder which are then due
except as otherwise defined in this Sublicense Agreement.

11.2 Upon early termination of this Sublicense Agreement in its entirety or with
respect to any country, under Sections 10.1 or 11.6 or due to a breach hereof by
Vanda, Vanda shall notify Novartis of the amount of Product that Vanda, its
Affiliates and Sublicensees then have on hand for sale in each country, the sale
of which would, but for the termination, be subject to royalty, and Vanda, its
Affiliates and Sublicensees shall thereupon be permitted to sell that amount of
Product, provided that Vanda shall pay the royalty thereon to Novartis, or HMRI,
as the case may be, at the time provided for.

11.3 Expiration or termination of this Sublicense Agreement or termination on a
country-by-country basis shall terminate all outstanding obligations and
liabilities between the parties arising from this Sublicense Agreement except
those described in Sections 6.2 (with sole respect to Novartis confidentiality)
6.3, 6.4, 6.5, 6.6, 6.8, 9.1, 9.2, 10.1, 10.2, 10.3, 11.1, 11.2, 11.4, 11.5,
11.6, 12.5, 12.6, 12.7, 14.1 and 14.2, which sections shall survive such
termination. In addition, any other provision required to interpret and enforce
the parties' rights and obligations under this Sublicense Agreement shall also
survive, but only to the extent required for the full observation and
performance of the surviving obligations under this Sublicense Agreement.

11.4 Except as otherwise specifically provided for herein, termination, in whole
or in part, of the Sublicense Agreement in accordance with the provisions hereof
shall not limit remedies to the parties which may be otherwise available in law
or equity, including consequential,


                                  Page 35 of 56

<PAGE>

incidental or indirect damages (such as loss of sales, profits, or goodwill)
arising out of a party's performance or nonperformance under this Sublicense
Agreement.

11.5 Subject to Section 11.2 and other express provisions hereof, upon early
termination of this Sublicense Agreement in its entirety due to breach hereof by
Vanda or pursuant to Sections 10.1, 10.2 or 11.6, Vanda's rights in the Compound
and Product shall cease, Vanda, its Affiliates and Sublicensees shall cease
manufacture, development, marketing and sale of the Compound and Product in the
Territory, and all originals and copies of Know-How, data, results and other
information collected and/or generated by Vanda, its Affiliates and Sublicensees
relating to the Compound or Product prior to termination shall be delivered to
Novartis within thirty (30) days thereafter, except for one copy thereof which
may be retained in Vanda's legal or other appropriately restricted files solely
for the purpose of establishing the extent of its obligations hereunder. Any IND
or other regulatory filing effected prior to termination shall be assigned by
Vanda to Novartis (or its designee(s), which designee may be HMRI or Titan), at
Novartis' request and expense, if not already assigned to Novartis. Vanda shall
provide to Novartis, within thirty (30) days of Novartis' request, copies of all
regulatory correspondence, including, but not limited to, IND Information
Amendments, IND Reports, IND Safety Reports, NDA submission, NDA Postmarketing
Reports, and reports of written/phone contacts to and from regulatory agencies,
as well as the safety database for the Product.

11.6 If (a) Vanda is precluded from selling the Product in a particular country
in the Territory by virtue of infringement of Third Party patent rights, or (b)
there is a holding of invalidity or unenforceability of any Patent, from which
no further appeal can be taken, that materially affects Vanda's ability to
commercialise the Product in a particular country in the Territory, Vanda shall
have the right but not the obligation to terminate this Sublicense Agreement in
such country. At Vanda's option, this Sublicense Agreement may be terminated in
its entirety if the events described in subsection (a) or (b) of this Section
11.6 occur in either the United States or two of the Major Market Countries.
Within ninety-five (95) days of any such termination, subject to the following
sentence, Novartis shall repay to Vanda if the Sublicense Agreement has been
terminated in its entirety, that portion of the up front license fee and
milestone payments it has received from Vanda up to the date of termination. In
the event that the Sublicense Agreement is terminated pursuant to Section 11.6
of the Sublicense Agreement, Novartis shall be obligated to make the foregoing
repayments to Vanda, but only to the extent that it has been repaid its own
up-front license fee and milestone payments due to Novartis under Section 11.6
of the Titan Agreement. If this Sublicense Agreement has been terminated only
with respect to certain country(ies), the parties shall negotiate in good faith
a smaller portion of the upfront license fee and milestone payments Novartis has
received from Vanda up to such date which shall be repaid to Vanda; provided,
however, if


                                  Page 36 of 56

<PAGE>

the Titan Agreement has been terminated only with respect to such certain
countries under Section 11.6 of the Titan Agreement, Novartis shall be obligated
to make such repayments to Vanda but only to the extent Novartis has been repaid
the corresponding portion of the up front license fee and milestone payments
owed to it pursuant to Section 11.6 of the Titan Agreement. If the parties are
unable to agree on such smaller portions within ninety (90) days, the issue
shall be submitted for determination by arbitration in accordance with Section
14.2.

12. WARRANTIES INDEMNIFICATIONS AND REPRESENTATIONS

12.1 Novartis represents and warrants that to the best of its knowledge at the
date of this Sublicense Agreement:

(a) all currently issued or pending patents and patent applications owned or
controlled by HMRI or its Affiliates or its Sublicensees claiming the Compound
or Product, are listed in APPENDIX A;

(b) HMRI or its Affiliates or its Sublicensees own or control the entire right,
title and interest in Patents and Know-How. If Novartis becomes aware of any
patents or patent applications owned or controlled by HMRI or its Affiliates or
Sublicensees claiming the Compound or Product or manufacture, formulation or
use thereof, not listed in Appendix A-and is within the rights granted to Vanda
in this Sublicense Agreement, such patents and patent applications shall be
added to APPENDIX A at no cost to Vanda. Novartis further represents and
warrants that to the best of its knowledge as of the date of this Sublicense
Agreement;

(c) the Titan Agreement is in full force and effect and neither HMRI nor Titan
nor Novartis is in default of any of their obligations thereunder;

(d) subject to obtaining HMRI's and Titan's prior written consent, each of
which has been obtained, Novartis has the legal power, right and authority to
enter into this Sublicense Agreement; and

(e) Novartis has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in the Patents or Know-How.

Vanda represents and warrants that it has the legal power, right and authority
to enter into this Sublicense Agreement.

12.2 Nothing in this Sublicense Agreement shall be construed as a warranty that
the Patents are valid or enforceable or that their exercise does not infringe
any patent rights of Third Parties. Novartis hereby represents and warrants that
it has no present knowledge (except as disclosed to Vanda or as available to
Vanda from public information) that (i) the Patents are invalid or
unenforceable, (ii) the exercise of Patents infringes any patent rights of Third
Parties, and (iii) Third Party licenses are necessary for the development,
manufacture or commercialization of the Compound or Product. A holding of
invalidity or unenforceability


                                  Page 37 of 56

<PAGE>

of any Patent, from which no further appeal is or can be taken, shall not affect
any obligation already accrued hereunder, but shall only eliminate future
royalties otherwise due under such Patent from the date such holding becomes
final.

12.3 Each party represents and warrants to the other that it is not currently
debarred, suspended or otherwise excluded by any U.S. Government agencies from
receiving federal contracts.

12.4 Vanda represents and warrants that during the term of this Sublicense
Agreement, neither it, an Affiliate or a Sublicensee shall license, develop,
have developed, manufacture, have manufactured, sell or have sold any of the
following compounds or products classified as an atypical antipsychotic [*].

In the event that Vanda or a Sublicensee undertakes any of the foregoing actions
within the EEA, then Novartis may not terminate this Sublicense Agreement or
seek damages or equitable remedies for such actions, but may at its option by
notice to Vanda (i) terminate the Exclusive nature of the licenses granted
pursuant to Article 2 hereof in the EEA, so that all use of Patents and Know-How
in the EEA will thereafter be on a non-exclusive basis at a reduced royalty rate
to be negotiated at time of change in exclusivity; (ii) cease providing
improvements to Vanda pursuant to Section 2.3; and/or (iii) require Vanda to
prove to Novartis' reasonable satisfaction that the Know-How is not being used
for such activities. Notwithstanding the foregoing, Novartis and Vanda agree
that in the event Vanda acquires rights to one or more of the [*] compounds or
products listed in the first paragraph of this Section 12.4 (the "Acquired
Compounds or Products") as part of a corporate transaction Novartis shall use
its good faith efforts to cause HMRI and Titan to waive any rights that it may
have against Vanda or Novartis under this Section 12.4 and Section 12.4 of the
Titan Agreement. To assist Novartis in obtaining such waiver from HMRI, Vanda
will provide Novartis with arguments supporting how Vanda intends to prevent the
Products from being negatively impacted by the Acquired Compounds or Products.
In the event that HMRI or Titan will not waive such rights and Vanda does not
agree to divest the Acquired Compounds or Products or, alternatively, sublicense
the Product to a mutually acceptable Third Party (which third party must also be
acceptable to HMRI and Titan), Novartis agrees that its sole and exclusive
remedy against Vanda shall be to terminate the Exclusive nature of the
Sublicense Agreement in the EEA as provided for in this Section 12.4, and to
terminate this Sublicense Agreement elsewhere in the Territory.

12.5 Vanda shall indemnify, defend and hold Novartis, HMRI, Titan and their
respective Affiliates harmless from and against any and all liabilities, claims,
demands, damages, costs,

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 38 of 56

<PAGE>

expenses, fines, penalties or money judgments including without limitation court
costs and reasonable attorney's fees (hereinafter referred to as "Liabilities"),
during the term of this Sublicense Agreement and after its expiration or
termination, incurred by or rendered against Novartis, Titan, HMRI and their
respective Affiliates which arise out of the clinical testing, use or labeling,
or the manufacture, processing, packaging, sale or distribution of the Compound
or Product (as the case may be) by Vanda, its Affiliates and Sublicensees, or
the breach of this Sublicense Agreement by Vanda (including without limitation
any breach of Vanda's' representations and warranties under this Sublicense
Agreement) or any negligence or misconduct of Vanda, except to the extent that
such Liabilities are directly attributable to the breach of this Sublicense
Agreement by Novartis or breach of the Titan Agreement by HMRI or Titan
(including without limitation any breach of Novartis' representations or
warranties under this Sublicense Agreement or any breach of HMRI's or Titan's
representations or Warranties under the Titan Agreement) or any negligence or
misconduct by Novartis, Titan or HMRI. Vanda shall also indemnify, defend and
hold Novartis, Titan, HMRI and their respective Affiliates harmless from and
against any and all Liabilities incurred by or rendered against Novartis, Titan,
HMRI and their respective Affiliates which arise out of the Compound or Product
supplied by Vanda to HMRI, Titan and/or Novartis and for use pursuant to Section
2.3, or which arise out of any contracts or arrangements with Third Parties
(including CROs) relating to, the development and/or registration process for
the Compound or Product from and after the Effective Date of this Sublicense
Agreement, whether such contracts or arrangements with Third Parties were
entered into prior to or following the Effective Date of this Sublicense
Agreement, except to the extent that such Liabilities are directly attributable
to the breach of this Sublicense Agreement by Novartis or breach of the Titan
Agreement by HMRI or Titan (including without limitation any breach of Novartis'
representations or Warranties under this Sublicense Agreement or any breach of
HMRI's or Titan's representations or warranties under the Titan Agreement) or
any negligence or misconduct by Novartis, Titan or HMRI.

12.6 Novartis shall indemnify, defend and hold Vanda, its Affiliates and
Sublicensees harmless from and against any and all Liabilities (as defined in
Section 12.5 hereof), incurred by or rendered against Vanda, its Affiliates and
Sublicensees; which arise out of the breach of this Sublicense Agreement by
Novartis (including any breach of Novartis' representations or warranties under
this Sublicense Agreement), or any negligence or misconduct by Novartis, except
to the extent that such Liabilities are directly attributable to the breach of
this Sublicense Agreement by a third party (including without limitation any
breach of Novartis' representations and warranties under this Sublicense
Agreement), or any negligence or misconduct by Vanda, HMRI or Titan. Novartis
shall also indemnify, defend and hold Vanda, its Affiliates and Sublicensees
harmless from and against any and all Liabilities incurred by or rendered
against Vanda, and its Affiliates and Sublicensees which arise out of


                                  Page 39 of 56

<PAGE>

the manufacture, use or sale of the Compound and Product that has been
manufactured or sold by or on behalf of Novartis and its Affiliates or
Sublicensees in those countries where Vanda's sublicense rights hereunder have
been terminated (including the clinical testing, use and labeling of the Product
and the manufacture, processing, packaging, sale or distribution of the Product
by Novartis and its Affiliates and Sublicensees) or subject to Section 5.4(b),
which arise out of the activities of any CRO which occurred prior to the
execution of this Sublicense Agreement and that were undertaken pursuant to a
written contract between Novartis and such CRO relating to the Compound or
Product.

12.7 Each party shall give the other prompt notice in writing of any claim or
demand referred to in Sections 12.5 or 12.6. In addition, the obligations of any
indemnifying party shall be subject to the indemnified party fulfilling the
following obligations:

(a) With respect to third parry claims, indemnified party shall fully cooperate
with the indemnifying party in the defense of such claim or demand which defense
shall be controlled by the indemnifying party; and

(b) With respect to third party claims, indemnified party shall not, except at
its own cost, voluntarily make any payment or incur any expense with respect to
any claim, demand or suit (including without limitation retaining its own
counsel) without the prior written consent of the indemnifying party, which such
party shall not be required to give.

13. FORCE MAJEURE.

13.1 If the performance of any part of this Sublicense Agreement by either
party, or if any obligation under this Sublicense Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the party required to perform, the party so affected, upon
giving written notice and written evidence of such force majeure to the other
party, shall be excused from such performance to the extent of such prevention,
restriction, interference or delay, provided that the affected party shall use
its reasonable commercial efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever
the force majeure is removed. In the event of a force majeure, the parties shall
also discuss whether modification of the terms of this Sublicense Agreement are
necessary to alleviate the hardship or loss caused by the force majeure.

14. GOVERNING LAW AND ARBITRATION.

14.1 This Sublicense Agreement shall be deemed to have been made in the State of
New York and its form, execution, validity, construction and effect shall be
determined in


                                  Page 40 of 56

<PAGE>

accordance with the laws of the State of New York (without regard to New York's
or any other jurisdiction's choice of law principles).

14.2 In the event of any controversy or claim arising out of or relating to any
provision of this Sublicense Agreement, the parties shall try to settle their
differences amicably between themselves. Any unresolved disputes arising between
the parties relating to, arising out of or in any way connected with this
Sublicense Agreement or any term or condition hereof, or the performance by
either party of its obligations hereunder, whether before or after termination
of this Sublicense Agreement, shall be resolved by final and binding
arbitration. Whenever a party shall decide to institute arbitration proceedings,
it shall give written notice to that effect to the other party. Except in the
case of a determination to be made where payments are to be made to by one party
to the other, the party giving such notice shall refrain from instituting the
arbitration proceedings for a period of sixty (60) days following such notice to
allow the parties time to further attempt to come to an amicable resolution of
the dispute. Arbitration shall be held in New York City, New York according to
the commercial rules of the American Arbitration Association ("AAA"). The
arbitration will be conducted by a panel of three arbitrators appointed in
accordance with AAA rules; provided, however, that each party shall within
thirty (30) days after the institution of the arbitration proceedings appoint a
party arbitrator, and the party-arbitrators shall select a neutral arbitrator,
to be chairman of the arbitration panel, within thirty (30) days thereafter. If
the party-arbitrators are unable to select a neutral within such period, the
neutral shall be appointed in accordance with AAA rules. All arbitrator(s)
eligible to conduct the arbitration must agree to render their opinion(s) within
thirty (30) days of the final arbitration hearing. No arbitrator (nor the panel
of arbitrators) shall have the power to award punitive damages under this
Sublicense Agreement and such award is expressly prohibited. Decisions of the
arbitrator(s) shall be final and binding on all of the parties. Judgment on the
award so rendered may be entered in a court having jurisdiction thereof. In any
arbitration pursuant to this Sublicense Agreement, the arbitrators shall
interpret the express terms hereof and apply the laws of the State of New York.
The losing party to the arbitration as determined by the arbitrators shall pay
the costs of arbitration. Notwithstanding the provisions of this clause, either
party may seek preliminary or injunctive measures or relief in. any competent
court having jurisdiction.

15. SEPARABILITY

15.1. In the event any portion of this Sublicense Agreement not material to the
remaining portions shall be held illegal, void or ineffective, the remaining
portions hereof shall remain in full force and effect.


                                  Page 41 of 56

<PAGE>

15.2 If any of the terms or provisions of this Sublicense Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.

15.3 In the event that the terms and conditions of this Sublicense Agreement are
materially altered as a result of Sections 15.1 or 15.2, the parties shall
renegotiate the terms and conditions of this Sublicense Agreement so as to
accomplish as nearly as possible the original intentions of the parties.

16. ENTIRE AGREEMENT

16.1 This Sublicense Agreement and the Appendices attached hereto, entered into
as of the date written above, constitutes the entire agreement between the
parties relating to the subject matter hereof and supersedes all previous
writings and understandings, including the Confidentiality Agreement between the
parties dated June 16, 2003 (it being understood and agreed that all
Confidential Information of HMRI, Titan and Novartis disclosed to Vanda prior to
the Effective Date of this Sublicense Agreement shall be subject to Sections
6.4, 6.6, 6.7 and 6.9 of this Sublicense Agreement). No terms or provisions of
this Sublicense Agreement shall be varied or modified by any prior or subsequent
statement, conduct or act of either of the parties, except that the parties may
amend this Sublicense Agreement by written instruments specifically referring to
and executed in the same manner as this Sublicense Agreement. Any amendments to
this agreement require the prior written approval of Titan and HMRI, which
approval will not be unreasonably withheld.

17. NOTICES

17.1 Any notice required or permitted under this Sublicense Agreement shall be
in writing and in English and shall be sent by airmail, postage prepaid, or
facsimile or courier to the following address of each party or to such other
address as may be designated in writing by the respective parties:

If to NOVARTIS:
Novartis Pharma AG
Legal Services
P.O. Box
4002 Basel
Switzerland
Facsimile: +41 61 324 68 59


                                  Page 42 of 56

<PAGE>

Attention: General Counsel Pharma Legal

With a copy to:
Business Development and Licensing
Novartis Pharma AG
P.O. Box
4002 Basel
Switzerland
Attention: Head of Global Partnering

If to Vanda:
Vanda Pharmaceuticals Inc.
47 Hulfish Street, Suite 310
Princeton, NJ 08542
Attn: Patricia Nasshom

17.2 Any notice required or permitted to be given concerning the Sublicense
Agreement or HMRI Agreement shall be effective upon receipt by the party to whom
it is addressed.

If to TITAN:
Titan Pharmaceuticals, Inc.
400 Oyster Point Blvd., Suite 505
South San Francisco, CA 94080
Attention: Louis R. Bucalo, M.D.
President & CEO
Telephone: (650) 244-4990
Facsimile: (650) 244-4956

With a copy to:
Titan Pharmaceuticals, Inc.
400 Oyster Point Blvd., Suite 505
South San Francisco, CA 94080
Attention: Sunil R. Bhonsle
Executive V.P & COO
Telephone: (650) 244-4990
Facsimile: (650) 244-4956
and
Loeb & Loeb LLP


                                  Page 43 of 56

<PAGE>

345 Park Avenue
New York, New York 10154
Attn: Fran Stoller
Phone: 212-407-4935
Facsimilie: 212-407-4990
e-mail: fstoller@loeb.com

If to HMRI:
Aventis Inc.
200 Crossing Boulevard
Mail Stop BX2 800D
Bridgewater, NJ 08807-0890
Facsimile: 908-231-3619
Attn: Senior Vice President, Corporate Development

With copies to:
Aventis Inc.
200 Crossing Boulevard
Mail Stop BX2 700A
Bridgewater, NJ 08807-0890
Facsimile: 908-231-4480
Attn: Vice President, Legal Corporate Development

For safety and Adverse Event Reporting:
AVENTIS Inc.
Global Pharmacovigilance & Epidemiology
Suraj Patel
License Partner Coordinator
200 Crossing Boulevard
PO Box 6890, BX4-400G
Bridgewater, NJ 08807-0890
USA
Fax: +1 908 231 4229 Phone: +1 908 541 5431
Email: suraj.patel@aventis.com

With copies to:
AVENTIS Inc.
US Regulatory Liaison
Kerry Rothschild


                                  Page 44 of 56

<PAGE>

License Partner Coordinator
200 Crossing Boulevard
PO Box 6890, BX2-209G
Bridgewater, NJ 08807-0890
USA
Phone: +1 908 231 2848
Email: kerry.rothschild@aventis.com
And,
AVENTIS Inc.
US Regulatory Coordination
Steve Caffe
License Partner Coordinator
200 Crossing Boulevard
PO Box 6890, BX2-209G
Bridgewater, NJ 08807-0890
USA
Fax: +1 908 541 5293
Phone: +1 908 231 5683
Email: steve.caffe@aventis.com

18. ASSIGNMENT

18.1 This Sublicense Agreement or any portions thereof and the sublicenses
herein shall be binding upon and inure to the benefit of the successors in
interest and assignees of the respective parties.

18.2 Vanda may assign this Sublicense Agreement to an Affiliate without the
prior written consent of Novartis, and in such event Vanda will continue to
guarantee the obligations of such Affiliate hereunder. Subject to the foregoing,
Vanda shall not have the right to assign this Sublicense Agreement to any Third
Party without the prior written consent of Novartis, Titan and HMRI, such
consent not to be unreasonably withheld; provided, however, that no such consent
shall be required in connection with an assignment in connection with any event
referred to in Section 18.3 below.

18.3 In the event of a consolidation, merger, acquisition which involves a
change in control of Vanda, this Sublicense Agreement shall remain in full force
and effect, and Vanda agrees to notify Novartis, Titan and HMRI. Consolidation,
mergers and/or acquisitions to which


                                  Page 45 of 56

<PAGE>

Vanda is a party which do not involve a change in control of Vanda shall not
require such notice.

18.4 In order for any assignment by Vanda of this Sublicense Agreement (which is
permitted by this Sublicense Agreement) to be valid, the assignee of such
assignment shall assume and agree to be bound by the provisions hereof.

19. FAILURE TO ENFORCE

19.1 The failure of either party to enforce at any time any provisions hereof
shall not be construed to be a waiver of such provision nor of the right of such
party thereafter to enforce each and every such provision.

20. AGENCY

20.1 Except as expressly set forth in this Sublicense Agreement, nothing in this
Sublicense Agreement authorizes either party to act as agent for the other or,
as to any third party, to indicate or imply the existence of any such agency
relationship. The relationship between the parties is that of independent
contractors.

21. FURTHER ASSURANCES

21.1 Each party hereto agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate
in order to carry out the purposes and intent of this Sublicense Agreement.

22. CAPTIONS

22.1 Captions are inserted for convenience only and in no way are to be
construed to define, limit or affect the construction or interpretation hereof.

23. MISCELLANEOUS

23.1 Both parties agree to discuss matters arising during the term of this
Sublicense Agreement in the spirit of co-operation and good faith and endeavour
to resolve any differences by mutual agreement whenever possible. If the parties
fail to reach agreement, either party may submit the matter for resolution
pursuant to Section 14.2.


                                  Page 46 of 56

<PAGE>

23.2 HMRI and its Affiliates shall be third party beneficiaries under this
Sublicense Agreement to the extent that this Sublicense Agreement inures to the
benefit of HMRI, with respect to Sections 2.1(a), 2.4, 2.5, 2.7, 2.9(a), 2.9(d),
2.10, 3.4(a), 3.5, 4.1(a), 4.2, 4.3, 5.2, 5.3, 5.5, 6.3, 6.4, 6.7, 8.1, 8.2,
8.4, 8.5, 8.6, 8.7, 8.9, 8.10, 8.11, 8.12, 8.13, 9.1, 9.3, 9.4, 9.5, 10.1(b),
11.5, 12.5, 17.2, 18.2, 18.3, 18.4, 23.2 and 23.3 with all rights and remedies
associated therewith.

23.3 Vanda covenants to Novartis that during the term of this Sublicense
Agreement, Vanda, its Affiliates and Sublicensees shall not violate the Federal
Foreign Corrupt Practices Act in the performance of its negotiations or
obligations hereunder.

   ***[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK - SIGNATURE PAGE FOLLOWS]***


                                  Page 47 of 56

<PAGE>

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the Effective Date.

                                        VANDA PHARMACEUTICALS, INC.


                                        By: /s/ Mihael Polymeropoulos
                                            ------------------------------------
                                            Mihael Polymeropoulos
                                            Chief Executive Officer


                                        NOVARTIS PHARMA AG


                                        By: /s/ Herve Girsault
                                            ------------------------------------
                                        Name: Herve Girsault
                                        Title: Head, Global Partnering
                                               Business Development & Licensing


                                        By: /s/ Tom Chakraborti
                                            ------------------------------------
                                        Name: Tom Chakraborti
                                        Title: Senior Legal Counsel


                                  Page 48 of 56

<PAGE>

                               List of Appendices

<TABLE>
<S>                               <C>
Patents and Patent Applications   Appendix A
blank                             Appendix B
blank                             Appendix C
blank                             Appendix D
blank                             Appendix E
blank                             Appendix F
Titan Agreement                   Appendix G
</TABLE>


                                  Page 49 of 56

<PAGE>

                                                                      APPENDIX A

HMRI PATENTS AND PATENT APPLICATIONS

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 50 of 56

<PAGE>

                                                                      APPENDIX B

BLANK


                                  Page 51 of 56

<PAGE>

                                                                      APPENDIX C

BLANK


                                  Page 52 of 56

<PAGE>

                                                                      APPENDIX D

BLANK


                                  Page 53 of 56

<PAGE>

                                                                      APPENDIX E

CRO CONTRACTS

NONE


                                  Page 54 of 56

<PAGE>

                                                                      APPENDIX F

SPECIAL COUNTRIES


                                  Page 55 of 56

<PAGE>

                                                                      APPENDIX G

TITAN AGREEMENT

                                      [*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                  Page 56 of 56

<PAGE>

                        ADDENDUM TO SUBLICENSE AGREEMENT

                                     between

                               NOVARTIS PHARMA AG

                                       and

                           VANDA PHARMACEUTICALS, INC.

This Addendum is part of the SUBLICENSE AGREEMENT that became effective on the
4th day of June, 2004, between Vanda Pharmaceuticals, Inc., a corporation
organized and existing under the laws of the State of Delaware and having its
principal office at 47 Hullfish Street, Suite 310, Princeton, NJ 08542
("Vanda"), and Novartis Pharma AG, a corporation organized under the laws of
Switzerland and having its principal office at Lichtstrasse 35, CH-4056, Basel,
Switzerland ("Novartis").

EXCHANGE OF INFORMATION AND CONFIDENTIALITY

The parties agree to be bound to the following terms, and hereby incorporate
them into the Sublicense Agreement.

     1.0 Privacy and Security of Pharmacogenetic samples and data

Vanda agrees that all pharmacogenetic information that it receives in connection
with this agreement, including any DNA samples and/or animal tissues treated
with the compound that may be provided for further studies in accordance with
the Sublicense Agreement terms, as well as any raw data and individual clinical
genetic data and information, will be maintained in a confidential and secure
manner, in full compliance with applicable United States (federal and state),
European Union, and other country specific regulations for privacy and security
of genetic data and samples and personally identifiable health information, and
will only be used and/or disclosed in accordance with those regulations. Vanda
also agrees to ensure that any of its affiliates, agents, vendors or other
business partners who receive any identifiable genetic information or data from
Vanda relating to the compound, shall adhere to the same standards of privacy
and security mandated by this Addendum and the Sublicense Agreement.


                                   Page 1 of 3

<PAGE>

     2.0 Privacy and Security of Adverse Event information.

Vanda agrees that all personally identifiable adverse event information that it
receives in connection with this agreement, including spontaneous adverse event
report forms from Novartis, will be maintained in a confidential and secure
manner, in full compliance with applicable United States (federal and state),
European Union, and country specific regulations for privacy and security of
personally identifiable health information, including any specific requirements
that may apply to adverse event reporting information, and will only be used or
disclosed in accordance with those regulations. Vanda also agrees to ensure that
any of its affiliates, agents, vendors or other business partners (excluding
health authorities) who receive any identifiable adverse event information from
Vanda relating to the compound, shall adhere to the same standards of privacy
and security mandated by this Addendum and the Sublicense Agreement.

     3.0 Compliance with Informed Consents.

Vanda will assume all obligations of Novartis contained in the informed consents
with the individual participants in the studies transferred to Vanda. In case
only the genetic information or study data of such studies is transferred to
Vanda, Vanda will comply with any request by Novartis pursuant to a disclosure,
deletion or destruction request received by Novartis from an individual
participant of such study.

     4.0 Indemnification

Vanda agrees to indemnify and hold harmless Novartis for damages and legal fees
that may result from any breach by vanda of paragraphs 1.0 and 3.0 of this
Addendum. Vanda shall also provide written notification to Novartis of any claim
against Vanda relating to a privacy or security breach involving data or
information provided to Vanda under this Addendum or the Sublicense Agreement,
within three (3) business days of receipt of such claim, lawsuit or
notification. Vanda agrees that Novartis shall be permitted to select counsel of
its own choosing in the event that a claim or lawsuit is filed that impacts
Novartis' interests.

  *** Remainder of page intentionally left blank, signature page to follow ***


                                   Page 2 of 3

<PAGE>

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the Effective Date.

                                        VANDA PHARMACEUTICALS, INC.


                                        By: /s/ Chip Clark
                                            ------------------------------------
                                        Name: Chip Clark
                                        Title: Chief Business Officer


                                        NOVARTIS PHARMA AG


                                        By: /s/ Herve Girsault
                                            ------------------------------------
                                        Name: Herve Girsault
                                        Title: Head, Global Partnering
                                               Business Development & Licensing


                                        By: /s/ Kimberly J. Urdahl
                                            ------------------------------------
                                        Name: Kimberly J. Urdahl
                                        Title: Head of Legal, Primary Care


                                   Page 3 of 3

<PAGE>

                   ADDENDUM NO. 2 TO THE SUBLICENSE AGREEMENT

                                     between

                               NOVARTIS PHARMA AG

                                       and

                           VANDA PHARMACEUTICALS, INC.


                                   Page 1 of 5

<PAGE>

This Addendum No.2 ("ADDENDUM") is part of the SUBLICENSE AGREEMENT that became
effective on the 4th day of June, 2004 ("AGREEMENT"), between Vanda
Pharmaceuticals, Inc., a corporation organized and existing under the laws of
the State of Delaware and having its principal office at 9605 Medical Center
Drive, Rockville, MD 20850 USA ("VANDA"), and Novartis Pharma AG, a corporation
organized under the laws of Switzerland and having its principal office at
Lichtstrasse 35, CH-4056, Basel, Switzerland ("NOVARTIS").

Save as expressly stated otherwise, defined terms (to be identified by their
first letter in capitals) shall have the same meaning in this Addendum as such
term is defined in the Agreement.

A. ADDITION TO APPENDIX A OF THE AGREEMENT

Novartis has filed a patent application covering additional Compound metabolites
as identified hereto in ANNEX 2, which hereby shall be deemed incorporated into
Appendix A of the Agreement.

B. NON-EXCLUSIVE PATENT LICENSE

Novartis hereby grants to Vanda under the patent covering a biomarker as
identified hereto in ANNEX 1 a license under the same terms as with respect to
the Novartis Patents under the Agreement however such license shall be: a)
non-exclusive and b) limited as far as such patent identified in ANNEX 1 covers
any aspects of Iloperidone;

Contrary to Section 8.3 of the Agreement relating to the other Novartis Patents,
Novartis will retain all financial, filing, maintenance and prosecution
(including oppositions) responsibility for the patent identified in ANNEX 1
hereto.

C. LEGAL EFFECT

Other than amended by this Addendum the Agreement shall remain in full force and
effect.

   *** Remainder of page intentionally left blank signature page to follow ***


                                   Page 2 of 5

<PAGE>

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in duplicates by their duly authorized representatives as of the date
of the last signature set hereto.

Rockville, February 16, 2006            VANDA PHARMACEUTICALS, INC.


                                        By: /s/ Chip Clark
                                            ------------------------------------
                                        Name: Chip Clark
                                        Title: CBO


Basel, February 20, 2006                NOVARTIS PHARMA AG


                                        By: /s/ CHRISTINA ACKERMANN
                                            ------------------------------------
                                        Name: CHRISTINA ACKERMANN
                                        Title: Head Legal Pharma,
                                               General Medicine


                                        By: /s/ Peter De Weerd
                                            ------------------------------------
                                        Name: Peter De Weerd
                                        Title: Authorised Signatory


                                   Page 3 of 5

<PAGE>

                                                                         ANNEX 1

[*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.


                                   Page 4 of 5

<PAGE>

                                                                         ANNEX 2

[*]

----------
CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                   Page 5 of 5